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Thesis Summary 
The object of this thesis was to investigate applications for monophasic action potential 
(MAP) recordings in the diagnosis and treatment of cardiac arrhythmias. To meet this 
objective, MAPs were measured in situ and in vitro, during sinus rhythm and cardiac 
arrhythmias. MAPs were analyzed for potential clinical applications and in novel cardiac 
mapping and ablation catheter concepts. 
MAPs are focal action potential recordings which are directly proportional to the 
electrical activities of cells adjacent to a contacting electrode. When sufficient force is 
applied between a contacting electrode and the myocardium, the cells directly beneath 
become mechanically depolarized; i.e. electrically inactive. As a transmembrane action 
potential passes through this region, a change in boundary currents between the active 
and inactive cells, via gap junctions, results in a waveform that is proportional to the 
original action potential. 
The Visible Heart® Apparatus provides us with the ability to study large mammalian 
hearts, including human, in an in vitro setting; allowing the testing of prototype catheter 
concepts prior to in situ or in vivo work.  To validate MAPs from an in vitro working 
heart model a comparison study was conducted. Over the course of 2 hours in situ and 2 
hours in vitro MAPs were recorded from the right atrium, left atrium, and right ventricle 
(endocardially and epicardially). Overall, there were no significant differences between 
recorded signals when compared to in situ baseline recordings. Based on these findings, 
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systems like the Visible Heart® Apparatus can be used as a platform on which cardiac 
action potentials can be studied.  
The clinical application of MAP recordings, as they pertain to radiofrequency (RF) 
ablations, was also evaluated. To ensure proper lesion formation, RF ablation requires a 
catheter contact force (CF) of between 10-20 grams to be maintained throughout energy 
delivery. It was determined that MAP waveforms could only be recorded when at least 
10-15 grams of CF was applied to the myocardium. In other words, the presence of MAP 
waveforms would indicate that sufficient CF has been applied prior to the delivery of RF 
energy. Additionally, MAP waveforms were found to correlate with RF lesion size. MAP 
amplitudes at baseline (pre-ablation) were significantly larger than amplitudes from 
lesions which matured to greater than 1 mm deep. MAPs were also able to distinguish 
between lesions between 1-2mm deep, and those deeper than 2mm. Moving forward, 
MAPs may be used in evaluating cardiac viability, both through recording from induced 
lesions, as well as in regions of scarred or ischemic myocardium. 
Finally, several novel catheter concepts for the recording of MAPs were designed and 
tested in situ and in vitro. Endocardial MAP recording concepts included catheters 
designed to target the pulmonary veins and surrounding atrial substrates. Additionally, an 
epicardial mapping system was developed for detecting ventricular tachyarrhythmias. All 
concepts illustrated an ability to elicit MAP recordings, however future catheter iterations 
should focus on optimizing the electrode-tissue interface, as well as the placement of a 
non-contacting reference electrode. 
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Section I: The Visible Heart® project as a platform for 
monophasic action potential recordings 
 
The focus of this section of is validating the Visible Heart® project as a viable in vitro 
platform for the study of monophasic action potentials (MAPs). For the study of 
electrophysiology catheters, it is critical for the conduction properties of the in vitro 
specimens to be unaltered from their intrinsic state. 
First, in this section I will present the current and historical perspectives on, and utilities 
of, MAP recordings. I will discuss how these waveforms can be implemented in 
conjunction with Visible Heart® methodologies to facilitate the rapid prototyping and 
development of novel catheters for the diagnosis and treatment of tachyarrhythmias, such 
as atrial fibrillation and ventricular tachycardia.  
Secondly, I will describe a validation study comparing in situ MAP recordings to those 
recorded in vitro, or on the Visible Heart® apparatus. This study provides information on 
the ability to record MAPs for several hours in situ and in vitro. It also shows the 
relationship between endocardial and epicardial waveforms from the right ventricle. 
Finally, this study can provide insight on how MAPs recorded from reanimated human 
hearts can translate to the clinical setting.  
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Using the Visible Heart® for studying cardiac monophasic 
action potentials and evaluating their underlying mechanisms 
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Preface 
We were invited to write a review article on the utility of the Visible Heart® Laboratory 
and the latest research we have been performing.  We chose to write this review on 
monophasic action potentials and Visible Heart® applications for prototype mapping and 
ablation catheters. 
The following manuscript provides a detailed review of current and historical literature 
associated with the recording of monophasic action potential (MAPs). MAPs have been 
used for a variety of clinical applications: e.g. action potential alternan mapping, 
arrhythmia susceptibility, lesion assessment and tissue viability. Using Visible Heart® 
methodologies, we are able to study these applications on a unique pre-clinical platform; 
with the added capability of in vitro human heart comparisons.  
I was responsible for the literature search conducted and documented in this section. I 
was also responsible for recording the MAP waveforms used in Figure 2. The 
arrhythmias collected and shown in Figure 3 were collected during a protocol where Dr. 
Tinen Iles, Maria Seewald, and I simultaneously evaluated cardiac viability through 
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different methods. Additionally, Dr. Mark Benscoter and I worked together to collect the 
contact force and MAP data represented in Figure 4. Finally, I developed the prototype 
catheter seen in Figure 5 with the technical expertise of Julia Campion (Medtronic, 
Mounds View, MN), Carla Pfeiffer (Medtronic), and Gonzalo Martinez (Medtronic). 
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Summary 
The Visible Heart® approach is a platform that allows for direct visualization and 
imaging of catheters inside of isolated large mammalian hearts. Over the last 20 years 
more than 1800 porcine, 10 mini-pig, 14 ovine, 14 canine, and 80 human hearts have 
been reanimated using this technology. This review describes the utilization of the 
Visible Heart® methodology as it relates to electrophysiologic studies to investigate the 
recording of monophasic action potentials (MAPs). We will describe the history and 
proposed mechanisms behind how MAPs are recorded, new catheters for recording these 
signals, and finally how we can utilize the Visible Heart® methodology to develop and 
test new MAP recording technologies for electrophysiologic investigations.  
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Historic perspective 
In 1882, the first report of cardiac monophasic action potentials (MAPs) was described 
by Burdon-Sanderson and Page [1]. Using two electrodes, one on healthy intact 
myocardium and the other on a nearby injured area, they recorded the first documented 
MAP waveform. In 1931 Schültz proposed another method of inducing focal myocardial 
injury, the Herzknoten or heart knot, where a tie was used to prevent local prefusion and 
produce the injury current [2, 3]. These original studies on MAP waveforms contributed 
to the belief that MAPs were only produced as a result of injury to the myocardium [2, 4, 
5]. 
Schültz continued his work, and in 1934 he created the first suction electrode technique 
for documenting reproducible cardiac MAP recordings [5]. Importantly, in 1969, this was 
taken a step further by recording in situ MAPs from the human ventricular endocardium, 
using a suction based catheter [6]. This pioneering work was then continued in humans, 
by Olsson et al., primarily on the right atrium [7, 8]. Despite these preliminary studies, 
and the development of transvenous catheters, such as those used by Stroobandt, the 
suction electrode technique was never widely adopted due to multiple concerns regarding 
patient safety [7, 9, 10]. Ultimately, the risks to the patients associated with using the 
suction-based catheters were deemed too great despite the identified and discussed 
clinical benefits that recorded MAP waveforms provided clinicians. However, thanks to 
the persistent work in this field by numerous subsequent cardiologists, scientists and 
device design engineers, MAPs can now be recorded safely and reliably in patients with 
contact catheters thereby opening the door to endless possibilities for improved patient 
outcomes. 
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The monophasic action potential recording electrode controversy 
In general, it is considered that MAPs are the result of a bipolar recording between two 
electrodes, where one electrode is located on inactive (blanked or injured) myocardium, 
and the second electrode is not. The latter could be on viable myocardium or not 
contacting the tissue at all but is electrically coupled via blood or another conductive 
medium to the former. Because bipolar MAP waveforms can only be recorded when two 
nearby electrodes are employed, it has been unclear which one is primarily responsible 
for the MAP recording. For example, Franz described in his 1999 review – “the 
extracellular nature of MAP recordings leads to debate over the electrode responsible for 
recording the waveforms, though many agree that the truth likely is a combination of 
both” [9]. About five years later Kondo et al. proposed a secondary theory in response, to 
what they called a “disagreement between these concepts” [11]. In response to these 
papers and many more, a multitude of studies were conducted over several years in an 
attempt to conclusively state which electrode, or more specifically “the myocardial 
electrical activity near which electrode”, was responsible for the resultant recorded MAP 
waveform. These studies have included a range of observations and conclusions stating 
MAPs can be the result of: 1) electrical activities near either or both electrodes, 2) injury 
currents, 3) superimposed electrograms, and/or 4) hybrid action potentials, just to name a 
few [12-20]. Nevertheless, these studies cumulatively have shown that the origin of the 
MAP recordings may be more complex than originally thought. Despite many of the 
aforementioned studies’ claims that one electrode or the other is the definitive source, the 
truth – as pointed out by Franz – is likely a combination of many of these theories.  
Nevertheless, all will agree as to the potential clinical investigational values of recording 
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these focal myocardial waveforms. 
Theories for relative electrode configurations 
As Schültz was introducing the suction electrode method for recording MAPs, another 
approach was also being simultaneously tested. In 1935, Jochim et al. reported that 
cardiac MAPs could be recorded by simply pressing a recording electrode against the 
myocardium [21]. Though discovered in the 1930s, the contact electrode technique was 
largely undeveloped as a clinically useful method until 1980, when Franz conducted a 
series of studies where he and colleagues were able to show that MAPs could be recorded 
by applying gentle pressure with a nonpolarizable electrode to the myocardium [22, 23]. 
This discovery that MAPs could be recorded without the need of a suction electrode, or 
the induction of myocardial injury, then opened the door for clinically safe MAP 
recordings in situ in humans. In addition to reduced patient risks, the contact electrode 
technique allowed physicians to record MAPs which were found to be stable over several 
hours. More recently, our lab has performed both in situ and in vitro studies (the latter 
employing Visible Heart® methodologies) where we have shown that MAPs recorded 
via the contact electrode technique can be done so both endocardially and epicardially for 
at least 2 hours with minimal catheter adjustments [24]. 
The contact electrode technique was supported largely by Franz’s work on the volume 
conductor theory, where it is claimed that MAP recordings are the result of changes in 
boundary currents [2, 9]. Franz drew these conclusions based on two key points: 
extracellular resistances have no influence on the recorded MAP waveforms and the 
relative numbers of cells contributing to a given MAP waveform has an impact on the 
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signal amplitude [2, 9]. Shown in Figure 1 is an illustration showing Franz’s hypothesis 
based on this theory. As the transmembrane action potential (TAP) passes the contact 
electrode, the boundary currents between the electrically active and inactive tissue are 
altered; the resulting waveform, or MAP recording, is then directly proportional to the 
original TAP. 
 
Figure 1. The contact electrode technique for monophasic action potential (MAP) recordings is 
documented. In the diagram, the transmembrane action potential (TAP) can be seen propagating past the 
tip electrode, causing changes in the boundary currents. The result is a MAP which is directly proportional 
to the underlying TAP waveform. Figure taken from: M. R. Franz, “MAPs recorded by contact electrode 
method,” in Monophasic Action Potentials Bridging Cell and Bedside, Armonk, New York: Futura 
Publishing Company, 2000.  
To the contrary, using an arterially perfused tissue wedge, Kondo et al. presented a 
scenario in which, by recording intracellular action potentials and traditional MAPs, they 
concluded that the contact, or KCl electrode in their study, was not the recording 
electrode; but in fact, it was the opposite, or the noncontact electrode which was the 
critical component in the resulting waveform [11]. This work also explored Franz’s 
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theory that the MAP sees deep into the tissue through an injection of ATX-II, which 
prolongs action potentials, directly beneath the contact electrode (about 3-4 mms deep) 
[9, 11]. However, it is important to point out that according to Franz’s theory, the cells 
directly beneath the catheter are inactive – and are never stated to be responsible for the 
MAP properties, it is the cells adjacent to the contact electrode which are responsible for 
the MAP and its corresponding properties [2, 9]. 
Clinical applications & utility 
Over the last 50 years, the prospect of recording MAPs from human heart tissue in situ 
has gone from a risky consideration to, for some, the “method of choice for evaluating 
repolarization” [19]. Specifically, Franz has illustrated many of the reasons why the 
monitoring of MAPs can or would be advantageous to evaluate cardiac electrical activity 
over electrograms or intracellular action potential recordings [9]. Numerous studies have 
documented the utility of recording MAPs in clinical scenarios, including: 1) to assess 
repolarization behaviors for conditions such as long-QT, or 2) the study of focal action 
potential behaviors in patients presenting with alternans during and atrial fibrillation (AF) 
[25-30]. Summarized in Table 1, are the reported MAP waveform properties documented 
for a variety of investigations performed on various species and/or with different 
recording catheters and techniques. Furthermore, we have been able to record MAP 
waveform properties from multiple locations throughout human heart so to critically 
study the heart’s conduction pathways: Using Visible Heart® methodologies on 
reanimated human hearts, we were able to record representative MAP waveforms from 
atrial and ventricular locations. Distinct waveform changes can be seen between all 
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recorded MAPs; specifically, the nodal like waveforms recorded from near the bundle of 
His (Figure 2). 
Table 1. Monophasic action potential properties reported from literature. 
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Figure 2. This diagram illustrates monophasic action potential waveforms recorded from a reanimated 
human heart. The waveforms have been normalized for both heart rate and amplitude to illustrate 
characteristic changes with anatomical locations. The bundle of His recording was collected 
endocardially, all other recordings were collected epicardially. 
The study of restitution dynamics is one area where cardiac MAPs have provided users 
with more information on arrhythmias, than a typical clinical electrogram.  Initially, Kim 
et al. set out to test if AF in humans, was related to the slope of the action potential 
duration (APD) restitution kinetics, and/or how that relationship could vary with chronic 
vs. paroxysmal AF [31]. Importantly, they observed that the APD restitutions were 
steeper in patients with AF, verses controls [31]. This publication was followed less than 
a year later by a report describing the implications of a steeper vs flatter restitution curve, 
and which of these factors was more indicative of arrhythmias [32]. In addition to the 
clinical applications, MAPs have been used to study and understand methods to test 
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restitution kinetics in both preclinical and translational models. For example, Osadchii, in 
2012, conducted a MAP study utilizing extra-systolic stimulation for generating 
restitution curves which provided results that deviate from those seen when dynamic 
pacing is used [33].  MAP restitution properties have also been studied with various 
global mapping models, such as that by Kalb et al., showing further potential for 
assessing focal arrhythmias [34]. They further described the abilities of MAP recordings 
to provide information on focal restitution properties, which in turn could be critical in 
the diagnosis and treatments of arrhythmias. Through further studies, MAP recordings 
could be used to tailor treatments based on a patient’s observed restitution kinetics to 
develop a more personalized course of medical treatment. 
The recording of MAPs has also been used extensively for the study of the clinical 
arrhythmias through action potential alternans: much of this research being performed by 
Narayan and his co-workers [27, 28]. In one of their patients with atrial flutter, MAPs 
were recorded during atrial pacing and they were able to show that APD rate 
maladaptation at the isthmus lead to alternans which could further disorganize causing 
either atrial flutter or AF [27]. Narayan also conducted a MAP study on 33 individuals 
showing APD alternans were more pronounced in more advanced stages of AF 
(persistent vs paroxysmal) [28]. In addition to these studies, work has also been done on 
the use of spectral analysis of MAP alternans to help identify specific patients who would 
be more likely to have substrates for AF [26]. This work and many more studies are 
summarized in a 2012 review by Franz [25].  In a manner similar to those mentioned 
above, the use of MAPs in today’s electrophysiology (EP) lab may lead to more tailored 
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treatment for all types of arrhythmias. Employing these technologies, it may be possible 
to predict individuals who are at higher risk for AF, which could lead to earlier diagnosis, 
treatment, and ultimately a higher quality of life for patients. 
As previously mentioned due to their ability to represent the underlying transmembrane 
action potential, MAPs recording in novel groups of patients may provide unique insights 
into abnormal myocyte repolarizations (also known as repolarization syndromes). For 
example, Blana et al. have conducted studies with mice genetically modified to express 
long QT syndrome type 3: they concluded that this model for long QT demonstrated both 
structural and electrophysiologic changes in atrial substrates [35]. Similarly, Shimizu et 
al. conducted some early studies on long QT syndrome and, through the study of 
afterdepolarizations, concluded that both verapamil and propranolol could help improve 
these abnormalities [36]. Interestingly, verapamil and propranolol have also been studied 
by other researchers, focusing on the ability to re-create a Brugada like action potential 
[37-40]. Recently, using Visible Heart® methodologies, we have initiated similar studies 
to generate Brugada-like action potentials in the right ventricular outflow tract of 
reanimated large mammalian hearts.  This model would allow us to monitor the focal and 
global applications of a variety of current and novel therapies for the treatment of early 
repolarization diseases. 
The study of MAP properties, could be greatly beneficial in the development and 
understanding of both new and existing chemical compounds. For example, previously 
Kågström et al. studied 12 different drugs with known effects on ventricular 
repolarization, to evaluate MAPs from guinea pigs compared to the known response in a 
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dog model [41]. Fossa et al. furthered this research by using the guinea pig model to 
demonstrate that Azithromycin as a standalone therapy, as well as in combination with 
chloroquine, had no additional arrhythmia risk [42]. Additional drug studies, with MAP 
verification, include those by Tabo et al.  in 2007, on delayed ventricular repolarization, 
and by Cheng et al. in 2011, on the effects of estradiol and progesterone [43, 44]. More 
recently, it was described that MAP recordings could also be used to link changes in 
electrocardiograms to potential causes through torsadogenic drugs [45]. This research 
highlights that as our understanding of arrhythmias evolves, so do the agents we treat 
them with. Incorporating the study of MAPs with the testing and development of these 
agents could lead to a more detailed understanding of their impact, and consequently the 
potential side effects.  
The ability to assess tissue viability and ablation lesions was initially studied with MAPs 
in 1984, by Franz et al.; they elicited MAP recordings in 41 dogs from ischemic and 
healthy regions of epicardial and myocardial tissue [46]. Franz was able to demonstrate 
MAP recordings were able to more accurately identify regions of myocardial ischemia 
than the study of the ST segment, and were also less dependent on the length of ischemic 
time [46].  Studies from our lab were not only able to confirm these early studies but also 
expand on them through the employment of multi-modal imaging allowing for direct 
visualization of the contact site.  In a recent study, we showed that one only needed an 
applied MAP catheter force of approximately 7.6 grams to reproducibly record MAPs 
over sustained periods: this was then applied to the recording of MAPs from lesions on 
the endocardial surface of the left atrium in a reanimated heart [47].  Coupled with the 
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Visible Heart® imaging, we were able to show the lack of MAP recordings on tissue that 
had been ablated, through direct visualization with endoscopes. In other words, we 
consider here that MAPs are able to easily distinguish between focal regions of healthy 
and ischemic myocardium; depending of catheter design this discrimination ability can be 
within millimeters: thus, an ablation catheter, with the ability to record MAPs, would 
provide physicians with feedback related to the device tissue interface as well as tissue 
viability before and after the applied therapy. 
Visible Heart® methodologies for electrophysiologic investigation 
Visible Heart® methodologies have been employed by our laboratory for over two 
decades, utilizing the study of large mammalian hearts under physiologic conditions 
coupled with imaging from endoscopes inside the heart to provide direct visualization of 
the device tissue interface. The original publications detailing the perfusion methods for 
large mammalian heart reanimation using a clear perfusate were published in 2000, by 
Chinchoy et al. (employing animal hearts) and in 2005 by Hill et al. in which human 
hearts were reanimated: these methods will be described briefly in the following 
paragraphs [48]. 
For the study of recovered/reanimated large mammalian hearts, either healthy animals, 
those eliciting specific cardiac pathologies, or with prior placed cardiac devices are 
placed under general anesthesia (mean alveolar concentration > 1.2) and ventilated using 
positive pressure ventilation. Next, a median sternotomy is performed and a cardioplegia 
cannula is inserted into the ascending aorta to administer a high potassium cardioplegia 
solution to the heart in a Langondorff perfusion, whilst cooling the organ prior to 
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excision.  As required for reanimation, the major vessels (aorta, superior and inferior 
vena cava, pulmonary veins, and pulmonary arteries) are cannulated. The heart is then 
flushed with a modified Krebs-Henseleit buffer and attached to the Visible Heart® 
apparatus. The heart is continuously perfused and warmed to 37° C during which 
spontaneous electrical activity will typically occur. Once the ventricular myocardium has 
reached normothermic temperatures, defibrillation shocks (typically at 34 J) are applied 
to elicit sinus rhythm: in rare instances spontaneous electrical activity will organize into 
sinus rhythm without the application of an external shock. At this point the heart is 
considered to be functioning, using intrinsic conduction pathways with no pacing or 
electrical stimulation being required. Endoscopes can then be inserted into the various 
cannulated vessels and the internal anatomy imaged while electrical signals, including 
MAPs, from a multitude of locations are simultaneously recorded [24, 47, 49-51]. The 
employed procedures and protocols have been reviewed and approved by the University 
of Minnesota Institutional Animal Care and Use Committee and ensure humane treatment 
of all animals as indicated by the “Guide for the Care and Use of Laboratory Animals” 
from the National Institutes of Health (NIH). 
Our laboratory continues to reanimate and study human hearts that were not deemed 
viable for transplant [52, 53]. Consent for research use is obtained by LifeSource 
(Minneapolis, MN, our local organ procurement agency) who also assists with 
procurement and transportation of the organs to our laboratory within 4-6 hours. Again, 
using typical transplant procedures, these hearts are excised and placed on ice for 
transport. Upon arrival, each patient’s gifted heart is cannulated and re-perfused and 
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reanimated, in the manner described above. These research protocols have been reviewed 
and approved by the Institutional Review Board, Human Subjects Committee at the 
University of Minnesota. 
Transcatheter electrophysiologic studies 
Using the described Visible Heart® methodologies, we have been able to uniquely study 
the device tissue interface using a variety of imaging modalities simultaneously. This 
enables us to directly visualize how both clinical and prototype catheters interact with the 
tissue alongside how these catheters would be visualized clinically. Relative to EP 
studies, our laboratory has utilized the Visible Heart® methodologies extensively in the 
study of both traditional pacing, with one or multiple leads, and more recently with 
transcatheter delivered leadless pacemakers [54-58]. We also have utilized clinical EP 
systems to recorded multiple electrical waveforms during an array of cardiac ablation 
technologies [47, 49, 59-61]. While these studies focus on how conduction pathways 
were modified through various cardiac therapies (pacing or ablation), the intrinsic, 
focally recorded conduction patterns have only recently been explored using Visible 
Heart® methods. 
Monophasic action potentials from reanimated large mammalian hearts 
Translational research 
Over the last 5 years, the study of MAPs using the Visible Heart® methodologies has 
been an area of interest. Within this broad spectrum of research one area of particular 
interest has been the recording of MAPs from a variety of anatomical locations in the 
reanimated animal and human hearts. To establish baseline comparisons, MAPs were 
recorded in situ (in the animal) and in vitro (on the Visible Heart® apparatus), from an 
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array of locations, for up to two hours. We consistently observed that in situ and in vitro 
MAP waveform recordings over a 2-hour recording period were not significantly 
different in action potential duration when compared to their baseline in situ recordings 
[24, 51]. While this work was conducted on swine hearts, it shows that intrinsic 
conduction pathways and properties are preserved during the reanimation process. This in 
turn gives us an indication that the MAP recordings obtained in reanimated human hearts 
would be a realistic representation of those that which would be recorded in a clinical 
case. It is important to note that the human hearts are deemed non-viable for transplant 
often because of histories of cardiac disease, myocardial infarcts, or prolonged cardiac 
downtime.   Nevertheless, the use of MAP recording in such cases may be a means to 
study the pathophysiological behavior of these conditions: i.e. mapping a region of 
infarct. Additionally, this study also showed a direct beat-to-beat comparison of right 
ventricular signals recorded from juxtaposed endocardial and epicardial locations [51].  
The study of MAPs from the juxtaposed ventricular locations can be directly translated to 
the study of dispersion of ventricular repolarization; i.e. in the study of Brugada 
Syndrome where the epicardial and endocardial surface repolarize differently. 
Enhanced understanding of electrophysiology assessments in reanimated hearts 
Through the use of Visible Heart® methodologies our laboratory has been able to place 
catheters capable of MAP recordings in specific locations, with high accuracy. These 
locations, both endocardial and epicardial can then be imaged using direct visualization 
with endoscopes or cameras, and/or simultaneously with fluoroscopy. To date, in several 
human hearts (n=7) that were reanimated, MAPs were collected from a variety of both 
endocardial and epicardial locations, as well as on the left and right sides of a given heart. 
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Using the MAPs collected we were able to construct a diagram illustrating these typical 
MAP recordings and their corresponding anatomical imaging. The results from these 
studies can be seen in Figure 2. Notably, bundle of His elicited more dome like, slow 
response, action potentials while more traditional fast response action potentials were 
elicited from the contractile myocardium (both atria and ventricles). 
Monophasic action potential recording for the study of arrhythmias 
In addition to studying reanimated hearts in sinus rhythms, we have been able to collect a 
significant amount of data recorded during arrhythmias. Recording MAPs during elicited 
arrhythmias may provide more information on how arrhythmias originate and how they 
can best be terminated. Swine are known to be a fairly arrhythmogenic species, and 
during our studies we have recorded a variety of arrhythmias. For arrhythmias studies, 
MAPs were recorded from four catheters simultaneously: one endocardial right atrial 
(RAn), one epicardial left atrial (LAp), and two right ventricular catheters (one 
endocardial, RVn, and one epicardial, RVp). Recordings during sinus rhythm show the 
activation pattern, and characteristic waveforms for each of the four catheter locations 
(Figure 3A). Premature ventricular contraction (PVC) are easily inducible in swine 
through external mechanical stimulation, in Figure 3B it can be see that the RVp MAP 
(most near the stimulus, or PVC origin) activates first, followed by the RVn catheter. The 
following atrial contraction does not elicit a ventricular contraction, due to the cells being 
in a refractory period. Finally, AF is induced through a burst stimulus in the left atrial 
appendage (note this can be done both in situ and in vitro); see Figure 3C. This rhythm 
strip shows a heart in AF spontaneously terminating into a sinus pattern. Through studies 
like these, evaluating multiple MAP recording catheters simultaneously coupled with 
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Visible Heart® imaging platforms and methodologies, we can better understand these 
arrhythmias, and how to better diagnosis and treat them. 
 
Figure 3. Shown here are monophasic action potential recordings from the right atrium endocardium 
(RAn), left atrium epicardium (LAp), and right ventricle endocardium and epicardium (RVn and RVp 
respectively). The top strip (A) shows the heart in sinus rhythm. The RAn can be seen activation prior to 
the LAp, and the RV signals occur almost simultaneously. In strip B a premature ventricular complex, 
indicated by the arrow, was induced through external mechanical stimulation. In strip C the heart is 
initially in atrial fibrillation, the rhythm organizes and spontaneously terminates near the end of the 
recording (see arrow). 
 
Visible Heart® methodologies in the study of cardiac ablations 
The Visible Heart® methodologies have also been used in studying cardiac ablation 
techniques and outcomes. The Visible Heart® has been utilized in studying multiple 
aspects of cardiac ablation. Studies have been published on topics ranging from 
transseptal puncture techniques, perforation forces during ablation, visualization of steam 
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pops, and lesion integrity to name a few [59, 60, 62-64]. Most recently MAPs have been 
used, in combination with the Visible Heart®, to study the transmurality and continuity 
of lesions.  In a 2015 publication by Benscoter and Iaizzo, they fixed a fiber Bragg 
grating adjacent to a MAP4 (Medtronic, LLC., Dublin, Ireland) catheter (Figure 4A, B). 
Using the Visible Heart® preparation, they were able to create linear lesions using 
radiofrequency energy on the endocardial surface, specifically a mitral isthmus line. They 
then advanced the MAP recording catheter (and the attached fiber Bragg) and recorded 
the amount of force required to elicit MAP like waveforms. In areas where no MAPs 
were elicited the applied force was also recorded.  This method for correlating catheter 
contact force with a fiber Bragg was also used to assess catheter angle, with respect to 
MAP waveforms (Figure 4C). The authors concluded that MAPs could be elicited from 
viable myocardium when around 10 grams of force was applied to the tissue [63]. We 
have continued this work in the Visible Heart® lab and have further concluded that the 
optimal range to elicit and record MAP waveforms is between 10 and 15 grams [64]. This 
force ranged is aligned with the acceptable range for contact forces for RF ablation and 
illustrates that MAPs can be used to supplement those recordings. 
 
Figure 4. A) Shown here is an illustration of the MAP4 catheter and attached Fiber Bragg as described in 
Benscoter’s work [63]. B) This configuration was then used to assess monophasic action potentials 
recorded from an endocardial left atrial line, correlating the recordings with contact force [63]. C) This 
method of contact force assessment, in combination with the MAP4’s distinct tip electrodes, could be used 
to determine catheter orientation. 
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Visible Heart® methodologies for prototype catheter testing 
Combining our ability to record MAPs on a clinical EP system, with the unique 
visualization capabilities of the Visible Heart® approach, provides a platform on which 
concepts and prototype catheters can be rapidly designed, tested, and re-configured. This 
is most evident though the ability to directly visualize the catheter/device and study how 
it interacts with the active or inactive myocardium. To illustrate this concept, we have 
employed a research MAP recording catheter, the MAP4, and placed it into the right 
ventricle of the reanimated heart. Because of the MAP4 catheters tip design with 4 
distinct recording (spherical tip) electrodes we were able to determine catheter orientation 
relative to the myocardium through the recording of MAPs from each tip electrode. In 
Figure 5A, a MAP catheter can be seen with 2 electrodes clearly embedded in the 
myocardium, and 2 electrodes not contacting myocardium; this results in MAP 
recordings from only 2 of the 4 tip electrodes. When the catheter is adjusted slightly 
(Figure 5B) all 4 electrodes become in good contact with tissue, and MAPs are recorded 
from all tip electrodes [50]. 
 
Figure 5. Shown in this figure are captures from video footage collected using the Visible Heart® 
apparatus to visualize the device tissue interface. A) The MAP4 catheter is seen with 2 tip electrodes in 
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poor/no contact with the myocardium; accordingly, 2 of the recording channels lack monophasic action 
potential (MAP) recordings. B) When the catheter was adjusted, and all 4 tip electrodes were in good 
contact with tissue, MAPs were elicited on all channels. Additionally, panels C-F show images of a 
prototype MAP recordings catheter. The catheter is shown exerting low (D), medium (E), and high (F) 
contact force on the tissue on the mitral annulus of a reanimated swine heart. This figure was modified 
from M. M. Schmidt, M. R. Franz, T. G. Laske, M. T. Stewart and P. A. Iaizzo, "In Vitro Evaluations of 
Cardiac Mapping Catheters Designs and Utilities: Employing Visible Heart® Methodologies," Journal of 
Medical Devices, vol. 10, no. 2, 2016. 
Additionally, the Visible Heart® has been used to study the device-tissue interface with a 
variety of prototype catheters. In Figure 5C-F are images collected during the assessment 
of a prototype MAP catheter. The catheter is a based off the design of a multi-array MAP 
catheter, as described in US Patent 8565851 B2 [65]. This catheter was modified from an 
existing multi-array ablation catheter (MAAC, Medtronic, LLC. Dublin, Ireland) to 
optimize MAP recordings. The catheter was then placed into a reanimated swine heart so 
to visualize the device tissue interface. The catheter was advanced against the mitral 
isthmus at varying contact levels (low, medium, and high) [50]. Subsequently, we have 
used these obtained images to gather feedback from physicians: this novel imaging has 
allowed us to develop the next generation of MAP recording catheters. Many of the 
limitations of the initial prototypes, specifically associated with the device/tissue 
interface may have gone un-noticed without the ability to directly visualize their 
applications. 
Expert commentary and five-year view 
The treatment of cardiac arrhythmias with ablation technologies and/or the use of 
antiarrhythmic drugs is effective in some patients dramatically affecting their quality of 
life. As described above, many groups have attempted to use MAP recordings as a means 
to better diagnose, and ultimately treat these arrhythmias. Despite some sustained degree 
of interest in MAPs by clinical electrophysiologists, there have been few catheters 
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designed to record them. This scarcity of devices may be rectified through the design and 
development of novel devices, with nearly 15 patents related to novel ways to clinically 
record MAPs having been filed or granted in the last year alone. Several of these patents 
are related to methods for assessing cardiac conduction through concepts such as basket 
style mapping catheters, balloon interfaces, and other multi-array electrode 
configurations [66-72].  
The considered clinical benefits of utilizing MAP recordings over standard electrical 
recordings are currently growing; however, their adoption into EP labs has been slow. 
Perhaps, with the FDA approval of the EasyMap MAP diagnostic catheter (MedFact 
Engineering GmbH, Lörrach, Germany), MAPs may begin the process of partially 
penetrating this clinical field [73]. Yet, the road for MAP adoption will not be an easy 
one; with current conventional mapping catheters being designed for specific anatomies 
and procedures, an array of MAP catheters will be needed for their use to become 
commonplace. Nevertheless, when compared to electrogram recordings, MAP 
waveforms can provide clinical information vital to the understanding, diagnosis and 
treatment of arrhythmias through their ability to represent focal activation timings, 
depolarization rates, durations, and repolarization waveforms. Additionally, the use of 
MAP recordings could mitigate the need for mechanical pressure sensors and use the 
recording platform of the ablation catheter to ensure contact, orientation, depth, and 
effectiveness of an ablation, without added mechanics and sensors to the tip, making the 
catheter smaller or adding room for other enhancements. 
We have described here how the use of in vitro models, such as the Visible Heart® 
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methodologies, can illustrate the utilities and applications when developing MAP 
methodologies and technologies. One such indication has been through the study of 
current catheters and the pros and cons of working with them. By visualizing their use 
inside reanimated hearts, engineers and scientists can assess and study nearly all 
components of a given catheter and how it interacts with a variety of cardiac tissues. For 
example, when considering the case of designing an endocardially deployed right 
ventricular ablation catheter: 1) Can it be manipulated to the intended target? 2) What 
anatomical structures must it traverse to get there? 3) Does the tip of the catheter need to 
be perpendicular/parallel to the myocardium? 4) How important is contact force? 5) Can 
the appropriate leverage be applied?  Such an extensive list of design criteria can be 
assessed by employing novel visualization approaches thereby expediting the 
development, application and physician training associated with bringing a novel catheter 
design to market. 
The nature of the MAP recording requires one contact and one non-contact electrode. 
Because electrode placements are vital component of the device design, one needs to 
design the next generation of MAP catheters to allow and maintain the desired focal 
contacts. Fortunately, such catheters can be constructed with electrodes in a variety of 
locations via rapid prototyping and consequently tested in realistic, in vitro, functional 
models. Nevertheless, the ability to visualize the electrodes inside of a functioning heart, 
allows a designer to optimize the electrode positions/contacts relative to the catheter body 
and thus ultimately increase the ability to quickly iterate MAP recording catheters. 
Our laboratory continues to enhance and expand the Visible Heart® methodologies and 
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its applications in electrophysiologic studies remain extremely promising. On a daily 
basis, new catheters and ablation technologies are being assessed on reanimated large 
mammalian hearts. These abilities combined with continued enhancements in imaging 
modalities such as endoscopes, fluoroscopy, echocardiography, and with computational 
systems for electrical mapping are being applied to the MAP catheter design process.  In 
other words, the combined use of these cutting-edge technologies will pave the way for 
both the rapid prototyping and development of MAP catheter concepts and aid in 
developing technologies that more rapidly navigate the regulatory process and 
consequently expedite the journey to clinical use. 
Conclusion 
To improve ablation procedural outcomes, new methodologies and catheters will be 
required to provide more precise, focalized electrical information of a given patient’s 
heart.  Even with a growing understanding of the disease states associated with cardiac 
arrhythmias and the highly competent electrophysiological tools currently available, one 
can still envision the need for MAP recording catheters. The recording of focal MAP 
waveforms can provide patient information related functional status of the underlying 
myocardium: e.g., is it arrhythmogenic, has it been ablated, is it a scar. Our laboratory 
has utilized Visible Heart® methodologies to study the potential clinical utilities of 
recording MAP waveform, how to optimize their recording and assess varying catheter 
designs. Through this testing we are hopeful that the time from concept to product can be 
reduced and that an array of MAP catheters can be put in the hands of physicians, where 
they will ultimately improve patient outcomes. 
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Preface 
The Visible Heart® Laboratory provides researchers with unique abilities to study 
cardiac anatomy and electrophysiology in an ex vivo setting of large mammalian hearts, 
including human. Past work has shown the utility of the Visible Heart® for the 
evaluation of cardiac pacing and relevant pacing thresholds; however, research on the 
relationship of in situ and in vitro MAP waveforms has been limited. 
I was responsible for protocol development and data collection with the aid of Dr. Paul 
Iaizzo, Dr. Tinen Iles, and Maria Seewald. I was also responsible for the exportation of 
data for analysis. Thuy Hoang and I worked together to develop a custom MATLAB 
script for MAP waveform analysis. I was responsible for all statistical analysis and the 
composition of this manuscript. Furthermore, I presented the preliminary results of this 
study at the Design of Medical Devices Conference in Minneapolis, Minnesota in April 
2017. 
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Summary 
Objective: For cardiac arrhythmia mapping and ablation procedures, the ability to record 
focal cardiac action potentials could aid in precisely identify lesions, scarred tissue, 
and/or arrhythmic foci. Our study objective was to validate the electrophysiologic 
properties of a routinely employed, large mammalian, in vitro working heart model.   
Methods: Monophasic action potentials (MAPs) were recorded from 18 swine hearts, 
during viable hemodynamic function both in situ (post-median sternotomy) and in vitro 
(using Visible Heart® methodologies).  We placed specially designed mapping catheters 
both in epicardial and endocardial locations. High-quality MAP signals were recorded for 
up to 2 hours, and MATLAB was utilized to evaluate relative durations and 
temporal/regional changes in waveform morphologies. 
Results: MAPs were reproducibly recorded from both epicardial and endocardial 
locations in situ and in vitro.  No significant differences were noted in right atrial 
endocardial, right ventricular endocardial, right ventricular epicardial, or left atrial 
epicardial waveforms when baseline recordings were compared to all other in situ and in 
vitro time points. Further, MAP duration between right ventricular endocardial and 
epicardial waveforms was not significantly different, in situ or in vitro.   
Conclusion: In vitro models like the Visible Heart® may be considered for the study of 
cardiac arrhythmias, the development of novel therapies, and/or preclinical testing of 
future cardiac mapping catheters and systems. 
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Introduction 
The rapidly evolving field of clinically applied cardiac technologies continues to rely on 
validation via preclinical platforms. For example, relative to cardiac arrhythmia mapping 
and ablation, the ability to record focal cardiac action potentials would enable precise 
identification of placed lesions, areas of scarred tissue, and/or the sites of arrhythmic foci. 
Further, the development of 3D navigation and electrical mapping systems—such as 
EnSite Precision™ (Abbott, Chicago, IL), Rhythmia HDx™ (Boston Scientific, 
Marlborough, MA), Carto® 3 (Biosense Webster, Irvine, CA) and CardioInsight™ 
Noninvasive 3D Mapping System (Medtronic LLC., Dublin, Ireland) – could benefit 
from focal mapping of myocardial potentials. In other words, with spatial resolutions on 
the scale of 2 to 7 mm, these aforementioned mapping systems are limited in their 
abilities to target focal cardiac activations and assess repolarizations [1-3]. 
One solution is to record focally, extracellular monophasic action potentials (MAPs); 
collected via the contact method [4]. MAP recordings are focal action potential 
waveforms, representative of underlying transmembrane action potentials. These signals 
can be recorded through the application of sufficient contact forces to the myocardium [4, 
5]. Given the focal nature associated with MAP recordings, these waveform’s features 
change in response to the distribution of ion channels in the underlying myocardium, i.e., 
MAPs recorded from the various heart chambers will have different depolarization and 
repolarization properties [6-9]. With regard to 3D mapping applications, recent studies 
have described the benefits of MAP recordings for identifying focal rotors in atrial 
fibrillation (AF); these investigators identified localized rotors in up to 96% of AF 
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patients referred for ablation [10, 11]. Therefore, incorporating the ability to record 
MAPs into clinically used ablation catheters could be critical for improving AF 
therapeutic outcomes. It should be noted that today, after a mean of 1.3 ablation 
procedures, recurrence-free success rates are approximately 80%, with rates only as high 
as 70% without the use of antiarrhythmic drugs; hence there is room for improvements 
[12]. 
The utility of employing in vitro studies over in situ work has long been known.  In vitro 
studies can have associated values such as increased relevance, lower costs, abilities for 
direct visualizations, and/or ease of use [13, 14]. Techniques developed to study isolated 
hearts include Langendorff preparations and arterially perfused tissue wedges [15, 16]. 
As with many in vitro setups, such techniques are not without limitations. Frequently, the 
morphologies of underlying action potentials are modified by changes in activation 
pathways: e.g., changes caused by cardiac pacing or by underutilization of stretch-
activated ion channels because of paralytic drugs, such as blebbistatin [16, 17]. Several 
investigators have studied the effects of cardiac isolation on altering action potential 
properties [18-21].  
In vitro perfusions and reanimations of intact mammalian hearts, through working heart 
approaches like the Visible Heart® methodologies (Medtronic/University of Minnesota, 
Minneapolis, MN USA), have demonstrated added benefits for studying, visualizing, and 
treating cardiac arrhythmias [22, 23]. More specifically, our laboratory has utilized 
Visible Heart® methodologies, for testing a variety of pre-clinical prototype devices [24-
28].   
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In the present study, our primary objective was to further validate the electrophysiologic 
utility of investigating reanimated swine hearts; to do so we compared in situ versus in 
vitro recorded MAPs from multiple anatomic locations. 
Methods 
Our experimental protocol has been previously described [29]. The University of 
Minnesota Institutional Animal Care and Use Committee reviewed and approved the 
employed procedures; all animals were humanely treated per the Guide for the Care and 
Use of Laboratory Animals. 
In situ setup 
Swine (n = 18) weighing between 60 to 80 kg were initially anesthetized with 500 mg of 
Telazol and 500 mg of methohexital. Then, each animal was intubated and maintained in 
a plane of deep anesthesia (mean alveolar concentration > 1.2). To enable access to the 
epicardial surfaces of a given swine heart in situ, we performed a median sternotomy on 
each animal and formed a pericardial cradle. Only hearts eliciting normal cardiac 
functions (native sinus rhythm) were included: pacing was not used. 
To record both epicardial and endocardial MAPs, we used four 7 Fr MAP4 catheters 
(Medtronic LLC., Dublin, Ireland). These catheters contain 4 independent spherical-tip 
electrodes (diameter, 0.9 mm) and a distal (spaced 5 mm) ring electrode. The catheters 
were placed on the epicardial and endocardial surfaces such that the tips, or contact 
electrodes, were perpendicular to the myocardium. For the in situ portion of these studies, 
the first catheter was placed endocardially in the right ventricle (RV) through an 
introducer in the jugular vein. Then, similarly the second catheter was placed 
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endocardially within the right atrium (RA) via a second introducer. These endocardial 
MAP4 catheters were placed utilizing fluoroscopy (Ziehm Vision R, Nuremberg, 
Germany). Next, the third and fourth catheters were positioned onto the epicardial 
surfaces of the RV and the left atrium (LA) using direct visualization. Stabilizing arms 
were used to hold introducers containing conductive gel so to maintain continuity 
between the tip and ring MAP4 electrodes.  
In vitro setup 
After completion of the in situ portions of these studies, we excised each heart using 
standard cardioplegia methodologies [22]. A cold, high potassium solution was delivered 
through a cannula placed into the aortic root, causing cardiac arrest within 30-60 seconds. 
Each heart was then carefully explanted, cannulated, and re-perfused within 60 minutes 
[22]. Subsequently, once positioned onto the Visible Heart® apparatus, each heart was 
perfused with warmed modified Krebs-Henseleit buffer. Upon reaching 36.5° C a 
defibrillation shock initiated functional contractions, and only hearts beating in native 
sinus rhythm were used in these studies.  
MAP4 catheters were again placed within and on the reanimated hearts. The endocardial 
recording catheters (RA and RV) were delivered through a cannula placed within the 
superior vena cava and visualized with endoscopes. The exact placements of the 
epicardial catheters (RV and LA) were done with direct visualization. In vitro, all 
catheters were positioned near their in situ recording locations (± 1 cm). As an additional 
means to best compare the in vitro waveforms with in situ recordings, all MAPs were 
recorded only during physiologic “working mode” in these reanimated hearts [22]. While 
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in working mode, the hearts maintained stable hemodynamic function as assessed by 
monitoring with echocardiography, pressure waveforms, and sonomicrometry crystals. 
The remainder of the in vitro time, during non-recording periods, was spent in right-sided 
working mode to preserve each hearts’ overall function.  
Signal collection and statistical analysis 
To record MAP waveforms, we used a CardioLab Recording System (GE Healthcare, 
Waukesha, WI) with a wide bandpass filter (0.05 to 1,000 Hz). MAP waveforms from 
each anatomical location were collected and monitored for 2 hours. Catheter positions 
and tip pressures were slightly adjusted, as needed, throughout these recording periods, in 
order to record high-quality MAP signals with these characteristics: (1) stable baselines, 
(2) sharp upstrokes, and (3) amplitudes ≥ 2 mV for ventricular signals; ≥ 0.5 mV, atrial.  
To analyze these high-quality MAP signals, we used a customized MATLAB 
(MathWorks, Natick, MA) script, optimized to selectively identify the amplitude of each 
MAP using its plateau phase (Figure 6).  For each peak identified, using a built-in peak 
detection function, we defined a reference window as a means to analyze one signal at a 
time.  To calculate the relative MAP amplitudes, we subtracted the baselines from the 
peak’s measured voltages. In instances where “spike and dome” morphologies were 
present, a moving average was used to selectively identify the plateau as the MAP 
amplitude (Figure 6, top panel). 
To determine action potential duration (APD) at 30%, 60%, and 90% repolarization 
(APD30, APD60, and APD90), we assessed the time from the start of the signal until 
repolarization to the specified percentage (Figure 6, bottom panel). To evaluate temporal 
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and regional changes in MAP morphology, we used APD30:APD90 and APD60:APD90.  
 
Figure 6. Top) Quantified amplitudes of monophasic action potentials. The top strip shows the initial 
amplitudes selected by the software peak detection function. The blue line represents a moving mean used 
to identify the maximal amplitudes of the plateau phase. Bottom) Properties of monophasic action 
potentials. Action potential duration at 30%, 60%, and 90% repolarization was determined from the start 
of the signal until repolarization to the specified percentage. 
We performed all MAP waveform analyses at 10-min intervals. The mean value at a 
given time point represents the averaging of 1 minute of data (i.e., S10 mean represents 
the mean of the MAPs recorded during the 10th in situ minute). All data are presented as 
the mean ± standard deviation.  We used 1-way analyses of variance (ANOVA) and, after 
excluding outliers, post hoc Tukey honest significant difference (HSD) tests. A P value of 
less than 0.05 was considered as significant. 
Results 
We recorded MAP waveforms from a given heart for 120 minutes, both in situ and in 
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vitro (n = 18). Throughout the in situ recording periods, the mean heart rates were 104 ± 
13 bpm versus 94 ± 20 bpm in vitro (Figure 7).  For each catheter location, the APD90, 
APD30:APD90, and APD60:APD90 were determined and are presented below (Tables 2-
5).  Excluded from our analyses were amplitudes (given its previously reported 
sensitivity to catheter contact force) [4] and the time point immediately after the delivery 
of a defibrillator shock to initiate reanimation, i.e., in vitro time points start with V10 
measurements.   
 
Figure 7. Sinus heart rates averaged for all 18 animals. The first portion of the figure shows heart rate in 
situ (S0-S120), with a transition to in vitro (V0-V120). 
 
Right atrium 
Overall, for RA MAP recordings, the mean in situ APD90 values were between 97.4 ± 
25.3 msec and 124.2 ± 50.2 msec; in vitro, between 84.9 ± 28.9 msec and 112.0 ± 77.8 
msec (Table 2). Per ANOVA with Tukey HSD tests comparing APD90 for all RA time 
points to the in situ baseline (S0) there were no significant differences in these values 
(Figure 8).  
The mean in situ APD30:APD90 ratios were 58.6% ± 19.1% versus 63.1% ± 18.0% in 
vitro. The mean in situ APD60:APD90 ratios were 77.7% ± 11.8% versus 81.5% ± 
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11.8% in vitro. No significant differences in APD30:APD90 or APD60:APD90 ratios 
were observed for any time point comparisons to baseline. 
Table 2. Right atrial endocardial monophasic action potential properties 
 
 
 
 
 Figure 8. Action potential durations (APDs) for monophasic action potentials (MAPs) recorded from the 
right atrial endocardium. The first portion of the figure shows APDs in situ (S0-S120) with comparisons to 
those from MAPs recorded in vitro (V10-V120). 
 
Left atrium 
Overall, for LA MAP recordings, the mean in situ APD90 were between 92.3 ± 25.9 
msec and 114.7 ± 69.2 msec versus between 77.1 ± 49.1 msec and 127.7 ± 69.2 msec in 
vitro (Table 3). No significant differences in APD90 values were noted for any time 
points comparisons (Figure 9).  
The mean in situ APD30:APD90 ratios at baseline were 54.6 ± 20.5% and the mean 
APD60:APD90 ratios at baseline were 78.4 ± 10.2%. When the in situ baseline values 
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were compared to all other time points no significant differences were observed. 
Table 3. Left atrial monophasic action potential properties 
 
 
 
Figure 9. Action potential durations (APDs) determined for monophasic action potentials (MAPs) recorded 
from the left atrial epicardium. The first portion of the figure shows APDs in situ (S0-S120) with 
comparisons to those from MAPs recorded in vitro (V10-V120). 
In our experimental design, epicardial LA signals were the most variable and difficult to 
collect for several key reasons. We observed that because a given heart was functioning 
within a pericardial cradle in situ, the lateral LA was wrapped closely by the pericardium, 
so typically the LA appendage was the only accessible portion of this chamber. Further, 
the LA appendage typically elicited large amount of motion and coupled with nearby left 
lung filling, these caused issues in terms of relative catheter stabilities. In addition, given 
its anatomic orientation, the catheter often rubbed against the pericardium during 
recordings. In the in vitro setup, perfusion to the left side of the heart was reduced during 
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right-sided working mode. This in turn resulted in decreases in left-sided volumes (since 
only the coronaries were being perfused), as well as reductions in LA catheter contact 
forces. These factors taken together, were considered to contribute to a reduced ability to 
consistently record LA MAPs. 
Right ventricle 
For RV MAP recordings, we used 2 catheters: 1 on the endocardial surface and another 
epicardially. For the endocardial MAPs, the mean in situ APD90 values were between 
151.0 ± 75.9 msec and 227.4 ± 68.0 msec; versus between 152.5 ± 54.5 msec and 201.4 ± 
33.6 msec in vitro (Table 4). No significant differences in endocardial APD90 values 
were noted between any studied time points (Figure 10).  
Table 4. Right ventricular endocardial monophasic action potential properties 
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Figure 10. Action potential durations (APDs) for monophasic action potentials (MAPs) recorded from the 
right ventricular endocardium. The first portion of the figure shows APDs in situ (S0-S120) with 
comparisons to those from MAPs recorded in vitro (V10-V120). 
For the epicardial catheter, the mean in situ MAP APD90 values were between 145.6 ± 
59.9 msec and 204.3 ± 62.7 msec and between 137.7 ± 29.8 msec and 180.7 ± 36.9 msec 
in vitro (Table 5). No statistically significant differences in the epicardial APD90s were 
noted for any time points (Figure 11). No differences in APD90 was noted between the 
RV MAPs recorded endocardially versus epicardially.   
Table 5. Right ventricular epicardial monophasic action potential properties 
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Figure 11. Action potential durations (APDs) for monophasic action potentials (MAPs) recorded from the 
right ventricular epicardium. The first portion of the figure shows APDs from the in situ (S0-S120) MAPs 
versus those from in vitro measurements (V10-V120). 
For the MAPS recorded with the endocardial catheter, the mean in situ APD30:APD90 
ratios were 65.0% ± 22.1% versus 54.3% ± 21.1% when recorded in vitro. The mean in 
situ APD60:APD90 ratios were 85.4% ± 13.7% versus 79.0% ± 13.6% in vitro. No 
significant differences in these ratios were noted.  
For MAPs recorded from the RV with the epicardial catheter, the mean in situ 
APD30:APD90 ratios were 67.5% ± 20.4% compared to 64.8% ± 18.4% for the in vitro 
MAPs. The mean in situ APD60:APD90 ratios were 87.0% ± 8.9% versus 85.2% ± 9.2% 
in vitro. Again, no statistically significant differences in these ratios were observed. 
Discussion 
Here we have shown the MAPs can be recorded consistently for up to 2 hours from swine 
hearts, either in situ or in vitro and from both the endocardial and epicardial myocardium. 
Overall, MAP durations compared to baseline did not significantly change for signals 
recorded over 2 hours in situ, as well as for those recorded for an additional 2 hours in 
vitro (Figure 12). Further, no significant differences in waveforms were noted per our 
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analyses of APD30:APD90 and APD60:APD90 ratios compared to baseline levels.   
 
Figure 12. Monophasic action potentials recorded at the S0, V30 and V120 time points. Variations in 
amplitudes were considered to be due primarily to variations in applied contact forces. 
While no statistically significant differences were observed for the analyses between the 
MAP waveforms recorded in situ and in vitro, it should be noted that there were large 
standard deviations associated with many of the variables measured. As with any such 
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physiologic study variations can occur, even though steps were taken to minimize these 
variations. As noted above, our MAP4 catheter placements for endocardial measurements 
in situ were done under the guidance of fluoroscopy and those in vitro were done with 
direct visualization for the epicardial catheter. Despite being able to see the catheters 
using the Visible Heart® preparation, the in vitro MAP4 catheters placements were close 
to those sites recorded from in situ, but likely not the exact same locations. In addition, 
because of the arrhythmogenic nature of the swine heart, RV catheter placements were 
limited deep within the RV apex (due to the induction of ectopic beats).  
For the continued development and validation of cardiac medical devices, preclinical 
animal models, both in situ and in vitro, are of both critical values.  To date, various 
experimental methods have been used to better understand underlying cardiac 
electrophysiologic principles and to optimize device designs, yet few have met the 
requirements for eliciting reproducible and accurate cardiac action potentials.  As 
mentioned above, many in vitro approaches (such as Langendorff preparations or isolated 
tissue wedges) are limited by employing paralytic agents that in turn inhibit stretch-
activated ion channels [15-16]. Furthermore, the ability to study in situ electrophysiologic 
properties in an in vitro setting, is considered invaluable for the study of focal electrical 
changes. Here we showed that the novel Visible Heart® methodologies, allowed us to 
preserve intrinsic cardiac functions, with a minimal effect on ones’ ability to record 
cardiac MAPs throughout the heart including epicardial and endocardial locations: note, 
many clinical ablations procedures performed today to treat ventricular tachyarrhythmias, 
utilize an epicardial approach. 
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The investigation described here, is not without limitations. For example, our laboratory 
has previously identified that to obtain stable MAP recordings, constant pressure must be 
maintained by the catheter, on the surface of the myocardium. To minimize force 
variabilities, we developed customized fixtures to hold and stabilize the catheters in place 
over the 2-hour recording periods; we did not assess the forces applied. It should be noted 
that in both in situ and in vitro setups, minor MAP4 catheter adjustments were required to 
maintain stable tip pressures. As noted above, we did not utilize pacing in this study; yet 
in future studies one may want to incorporate atrial pacing or perform pace mapping so to 
study various arrhythmia models. Finally, left ventricular MAP recordings were not 
included in this study; future studies should be performed to incorporate additional 
anatomical locations, as well as utilize reanimated human hearts to provide more 
evidence for the translational values of such preclinical studies. 
Conclusion 
This study validated the utility of employing the Visible Heart® in vitro model, as a 
means for investigating electrophysiologic behaviors using MAP waveforms. 
Reproducible, endocardial and epicardial MAP recordings were obtained in situ as well 
as in vitro from multiple cardiac locations (RA, RV, and LA). The use of pre-clinical in 
vitro models is considered invaluable for the study of cardiac arrhythmias, the 
development of novel therapies, and/or the early testing of future cardiac 
mapping/ablation catheters or other devices. 
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Section II: Clinical utility of monophasic action 
potential recordings: contact force and focal tissue 
viability 
The second section of my thesis will focus on the clinical utility of monophasic action 
potential (MAP) recordings. In the past, MAPs have been used in the study of action 
potential alternans and their implications in patients with atrial fibrillation (AF). We 
would like to further explore the applications of MAPs in AF patients, specifically their 
utilities in radiofrequency (RF) ablation of the pulmonary veins and other AF substrates: 
i.e. left atrial appendage, posterior wall, and mitral isthmus. 
The formation of a proper lesion with RF energy requires a minimum of 10-20 grams of 
catheter contact force. It is also known that MAP waveforms can only be elicited when 
sufficient force is applied to the myocardium by the tip electrodes. The first portion of 
this section will describe in detail a series of studies which were conducted to determine 
the optimal force for MAP recordings, and how this knowledge can be applied clinically. 
While CF is required for lesion formation, the force applied during RF delivery can be 
unstable and the resulting lesion sizes may vary.  As a secondary method to validate 
lesion formation, MAP waveform properties were correlated to induced RF lesions: 
qualitatively and quantitatively. Based on the results from these two studies MAPs could 
be used both as a method to identify catheter CF prior to the delivery of RF energy, as 
well as a tool to evaluate lesion formation.   
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Preface 
Radiofrequency (RF) ablation is a common energy modality used in the treatment of 
cardiac arrhythmias. In order to create a lesion with RF energy, a minimum of 10 grams 
of contact force (CF) is required. It was hypothesized that because monophasic action 
potentials (MAPs) require CF to be recorded, they could be used as a supplement to CF 
measurements. 
The experimental protocol described in this section was developed by the co-authors, in 
which Dr. Mark Benscoter took a lead role. I assisted Dr. Benscoter with the collection of 
CF and MAP waveforms. Additionally, I was responsible for the detailed data and 
statistical analyses. I took on the primary responsibility for the preparation of this 
manuscript. 
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Summary 
Objective: Catheter contact force (CF) plays a major role in radiofrequency (RF) 
ablation; impacting lesion sizes, arrhythmia recurrence rates, dictating ablation durations, 
and/or overall patient safety. Our study sought to determine the relative CFs required to 
elicit reproducible monophasic action potential (MAP) recordings.  
Methods: The study utilized 4 swine in which: 1) median sternotomies were performed 
and MAPs were collected from 7 ventricular locations on the epicardial surface of each 
heart and 2) a subset of endocardial signals were recorded from a reanimated heart. In 
such studies, the initial elicitations and then losses of stable MAP waveforms were 
recorded as were their associated catheter CFs (n=371) using a calibrated optical fiber. 
Results: Mean CFs at the onset of MAPs were 14.2±2.9g for epicardial and 16.6±2.5g 
endocardial locations. Across epicardial locations, no significant differences in CFs were 
required to elicit MAPs. Additionally, endocardial and epicardial CFs for MAPs did not 
significantly differ from their respective locations; i.e. right ventricular septum 
endocardial versus epicardial.  
Conclusion: In our study, the catheter CFs required to elicit MAPs were within the 
ranges previously reported for clinically viable RF ablations. We believe that MAP 
recordings could be used to estimate the contact force of an RF ablation catheter, 
providing additional clinical feedback for physicians performing RF ablation. 
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Introduction 
In recent years, the incorporation of contact force (CF) sensing into radiofrequency (RF) 
ablation catheters, such as the ThermoCool SmartTouch® (Biosense Webster, Inc., 
Diamond Bar, CA) and the TactiCath™ Quartz (Abbott Laboratories, Chicago, IL), has 
led to increases in both cardiac ablation safety and success [1, 2]. Natale et al. reported 
the mean CF applied during irrigated RF ablation was 17.9 ± 9.4 g; when they achieved 
the target CF in patients with paroxysmal atrial fibrillation (AF), the recurrence-free rate 
at 12 months markedly improved [3]. Studies on mapping ventricular tachycardia have 
also looked at CF. Percutaneous subxiphoid access has been used as a means for both 
mapping and ablation of the epicardial substrate [4, 5]. In patients with ventricular 
tachycardia, Mizuno et al. reported that 9 g of CF was sufficient for mapping both 
endocardial and epicardial substrates [6]. 
Presented here is a new approach for estimating contact force by recording monophasic 
action potentials (MAPs) before applying ablative energy. The focal electrical signals 
represented by MAPs can be reproducibly recorded only when sufficient catheter CF is 
applied to the myocardium, resulting in a mechanical depolarization of cells by the 
electrode on the tip of a given catheter [7, 8]. The relationship between MAPs and 
intracellular action potentials has been previously explained. MAPs are the result of 
changes in boundary currents at the tip of the catheter. When sufficient CF is applied to 
the myocardium, the cells beneath the catheter become mechanically depolarized through 
the activation of stretch activated channels; thus, these cells are electrically inactive. As a 
transmembrane action potential passes through a given myocardial region, a change in 
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membrane voltage can be recorded between tip and distal catheter electrodes. The 
recorded waveforms provide useful insights into relative activation time, depolarization, 
and repolarization [7-9]. In other words, given its nature, a MAP cannot be recorded 
without certain applied catheter CF; however, the specific amount of CF required has not 
been previously studied.  
In this study, MAPs and CFs were simultaneously recorded from the epicardial and 
endocardial surfaces of swine hearts in situ and in vitro. The MAP waveforms 
supplemented CF recordings with data on focal electrical activity. If applied clinically, 
such MAP recordings could improve ablation outcomes in patients with cardiac 
arrhythmias. 
Methods 
For these studies 4 Yorkshire crossbred swine (weight, 75 to 95 kg) were anesthetized 
with Telazol® (Zoetis, Parsippany, NJ; 5 to 7 mg/kg) and methohexital (5 to 7 mg/kg), 
then intubated for general anesthesia with isoflurane (mean alveolar concentration > 2). 
After performing a median sternotomy, a pericardial cradle was created to enable access 
to the epicardial surface of each heart [10]. Only specimens that elicited normal cardiac 
function (e.g., native sinus rhythm) were included. The Institutional Animal Care and Use 
Committee at the University of Minnesota reviewed and approved these studies, which 
adhered to the Guide in the Care and Use of Laboratory Animals. 
Epicardial monophasic action potential recordings 
For MAP recordings, a catheter consisting of 4 spherical tip electrodes (diameter, 0.9 
mm) and 2 ring electrodes (width, 1 mm) was used (Figure 13). For epicardial recordings 
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the catheter was fixed to a micromanipulator, enabling precise adjustments to catheter 
positions in the x, y, and z directions. Using electrode gel, focal transmembrane 
waveforms were recorded in a bipolar configuration between each of the spherical tip 
electrodes and the distal ring electrode (spacing, 2 mm). Recordings were filtered using a 
bandpass filter of 0.05 to 1,000 Hz and a sampling frequency of 1,000 Hz. Signals then 
passed through an Octal Bio Amp (ADInstruments Ltd, Dunedin, New Zealand) and were 
recorded using a PowerLab system (ADInstruments Ltd).  
 
Figure 13. Illustration of the MAP4 catheter with spherical tip electrodes and ring reference electrodes. 
The fiber Bragg grating is attached to the side of the catheter through a hypotube. The image on the right 
demonstrates how the catheter and fiber Bragg interacts with the myocardium. 
Epicardial MAPs were recorded from a total of 7 predefined locations: the right 
ventricular (RV) apex, the RV anteroseptal border, the RV septum, the RV outflow tract 
(RVOT), the left ventricular (LV) anteroseptal border, the LV septum, and the LV apex 
(Figure 14). A reproducible ventricular MAP waveform was defined as a signal with the 
following characteristics: (1) stable baseline, (2) sharp upstroke, (3) amplitude > 5 mV, 
and (4) MAP signal duration of 200 to 400 msec, depending on the baseline heart rate. 
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Figure 14. Schematic of the epicardial monophasic action potential recording locations on the swine heart. 
 
Contact force 
To record applied CF by a given catheter, a fiber Bragg grating was mounted along the 
shaft of the catheter through an attached hypotube. The fiber was aligned so that it and 
the electrodes simultaneously contacted the myocardium (Figure 13). Each fiber was 
calibrated using an optical interrogator (HBM Test and Measurement, Darmstadt, 
Germany) against a compliant sponge to mimic myocardial stiffness. Doing so created 
linear calibration curves, which were then used to determine the relationship between the 
change in wavelength and CF. The calibration curves for the fiber Bragg gratings used 
yielded R2 values of 0.997 and 0.989 (Figure 15). Each experiment included a baseline 
recording at 37º C to adjust for frequency variations associated with changes in 
temperature.  
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Figure 15. Linear calibration curves for the fiber Braggs used in these experiments relating the change in 
wavelength to a predetermined force. 
To simultaneously evaluate the relationship between MAP and CF recordings, gradually 
increasing force was applied to the epicardial surface of the heart until 4 consecutive and 
reproducible MAPs were recorded (Figure 16A). Upon completion of data collection, 
force values during diastole and systole were averaged; the mean was defined as the CF 
required for MAP acquisition, also referred to as CF at “capture”. To account for any 
possible hysteresis effects, such as those seen while capturing pacing thresholds, CF was 
substantially increased and then the catheter was slowly retracted until reproducible MAP 
waveforms were no longer recorded, which was defined as “loss of capture” (Figure 16B) 
[11]. Throughout the experiments, investigators were blinded to the CF required for MAP 
recordings. During recordings, breath holds were induced to minimize any effects of 
respiratory movement against the fiber. 
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Figure 16. Illustration of collection protocol. A: Slowly increasing contact force (CF) was applied until 4 
consecutive high-quality monophasic action potentials (MAPs) were observed. B: At MAP capture, CF was 
substantially increased. C: The catheter was then slowly retracted until reproducible MAP waveforms were 
no longer recorded. 
 
Endocardial monophasic action potential recordings 
A subset of data was collected from the endocardial surface of a reanimated swine heart. 
After injecting cardioplegia, the heart was procured and reanimated using previously 
described Visible Heart® methodologies [12]. Heart rate and blood pressure were both 
stable throughout the recording period (96 bpm and 80/60 mmHg respectively). To obtain 
endocardial recordings the catheter was inserted into the right atrium (RA) through the 
superior vena cava. Then the catheter was manually navigated to 3 RA locations: the RA 
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appendage ostium (RAAO), the tricuspid valve annulus, and the coronary sinus ostium 
(CSO). Additional data were collected from these RV endocardial locations: the RV 
apex, the RVOT, the anterior papillary muscle, and the RV septum. Catheter force was 
slowly increased until 4 consecutive MAP recordings were captured, then the catheter 
was retracted and the measurement was repeated. 
Statistical and data analyses 
For each epicardial location, as well as for each anatomic location, statistical assessments 
of the variations in CF at capture and at loss of capture were made. Continuous variables 
are presented as the mean ± standard deviation. Both analysis of variance (ANOVA) and 
the Tukey post hoc test were employed. A probability valve of P < 0.05 was considered 
to indicate statistical significance. 
Results 
MAPs were recorded from 7 epicardial ventricular locations on 4 swine hearts, for a total 
of 315 measurements. Each of the swine had a stable sinus rhythm; throughout the in situ 
recording periods, the mean heart rate was 92 ± 10.4 bpm and the mean blood pressure 
was 106/57 ± 14.7/9.3 mmHg. At MAP capture, the mean CF for epicardial recordings (n 
= 159) was 14.2 ± 2.9 g; for endocardial recordings (n = 56), mean CF was 16.6 ± 2.5 g. 
At initial MAP capture, the overall mean CF was 14.8 ± 3.0 g. 
Hysteresis 
For each epicardial location, the relative CF required to initiate, and then lose, reliable 
MAP recordings were documented (Figure 17). Across all predefined locations, the mean 
CF at MAP capture was 14.2 ± 2.9 g (n = 159). At loss of capture (n = 156), the mean CF 
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was 13.5 ± 3.1 g. The mean difference in CF at capture vs. loss of capture was 0.9 ± 3.1 
g.  
 
Figure 17. Mean contact force (CF) at monophasic action potential (MAP) capture vs. loss of capture, 
plotted with the standard deviation for 7 epicardial locations where we simultaneously recorded MAP and 
CF. Sample sizes at capture/loss of capture were as follows: RV Apex n = 24/24, RV anteroseptal border n 
= 24/22, RV Septal n = 31/31, RVOT n = 24/24, LV anteroseptal border n = 16/15, LV Septal n = 16/16, 
and LV Apex n = 24/24. The only statistically significant difference (P < 0.05) was for the LV anteroseptal 
border. RV= right ventricular; RVOT = RV outflow tract; LV = left ventricular. 
The overall mean CFs at capture vs. loss of capture did not significantly differ. However, 
for the LV anteroseptal border (n = 16), the mean CF at capture was 15.4 ± 2.8 g, 
significantly higher (P < 0.05) than the mean CF at loss of capture of 12.2 ± 3.6 g. The 
mean difference for that location was 4.0 ± 5.1 g. No other significant differences in CF 
at capture vs. loss of capture were observed. 
Anatomic variations 
At MAP capture, the LV septum (n = 16) required the lowest mean CF, 12.6 ± 1.2 g, 
while the LV anteroseptal border (n = 16) required the highest, 15.4 ± 2.8 g (Figure 18). 
Nevertheless, no statistically significant differences were found in CF among the 7 
epicardial locations studied.  
In all instances, a minimum of 7.5 g of CF was required to elicit reproducible MAP 
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waveforms. The optimal range of CF for successful RF ablation is 10 to 15 g [4, 6]. 
Overall, 68.4% of CF values for MAP recordings occurring on the LV (39 of 57) were in 
that optimal range. In addition, 3 of the 4 RV locations (the RV anteroseptal border, the 
RV septum, and the RVOT) had a majority of their CF values for MAP capture in the 
same optimal range (n = 42 of 79 or 53.2%). The RV apex (n = 24) consisted of a larger 
range of CFs (7.5 to 19.4 g), but the mean CF at capture (14.3 ± 4.1 g) was within the 
optimal range. 
 
Figure 18. Contact force (CF) at monophasic action potential (MAP) capture, plotted for 7 epicardial 
locations where we simultaneously recorded MAP and CF. The shaded region is the optimal range (10 to 
15 g) for MAP recording. LV = left ventricular; RV = right ventricle; RVOT = right ventricular outflow 
tract. 
 
Endocardial contact force 
From the reanimated swine heart (Figure 19), CF at MAP capture was documented for 7 
endocardial locations (n = 8 per location). At capture, the mean CF in the RV was 17.0 ± 
2.0 g; in the RA, 16.0 ± 3.0 g. No statistically significant differences in CF between the 
RV endocardial locations were found. The CSO, in the RA, showed a significantly lower 
CF at capture than all other endocardial locations (P < 0.05). 
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Figure 19. Contact force at monophasic action potential capture from the endocardial surface of 1 
reanimated swine heart. The coronary sinus ostium showed a significantly lower force at capture than all 
other endocardial locations (P < 0.05). RAAO = right atrial appendage ostium; RV= right ventricular; 
RVOT = RV outflow tract. 
Finally, both endocardial and epicardial data at MAP capture for the RV apex, RV 
septum, RVOT, and RV septum was compared. For the RV apex, the mean endocardial 
CF was 17.6 ± 2.8 g; epicardial, 14.3 ± 4.1 g. For the RV septum, the mean endocardial 
CF was 16.8 ± 0.6 g; epicardial, 14.5 ± 3.3 g. Finally, for the RVOT, the mean 
endocardial CF was 16.9 ± 2.8 g; epicardial, 14.3 ± 2.6 g. We found no statistically 
significant differences in the endocardial vs. epicardial CF required to capture MAP 
waveforms. 
Discussion 
Over the last 10 years, the benefits of real-time CF measurements during the delivery of 
ablative cardiac RF therapies have been extensively explored. But the described benefits 
have focused on the size and relative transmurality of lesions. For example, in a canine 
study, atrial tissue lesions were identified to be transmural with applied catheter CF of 10 
to 20 g [13]. Further, other investigators have reported that the application of moderate 
CF is as important in determining lesion size as the applied RF energy and duration of the 
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therapy [14]. More specifically, those claims have been validated by the results of both 
the TOCCATA and EFFICAS I trials. In the TOCCATA trial, all ablations conducted at a 
CF < 10 g were associated with recurrence of AF by 12 months [15]. A combined 
analysis of the EFFICAS I and TOCCATA trials revealed that 20 g of CF should be used 
clinically, and that no less than 10 g should be applied during RF ablation [15, 16]. 
One of the major obstacles in ablation, even with real-time CF recordings, is catheter 
stability [1]. In clinical trials using catheters for CF recordings, a high variability in CF 
was noted within a single ablation, indicating the difficulty of maintaining stable 
recordings [1]. For example, during a single recording, CF varied by up to 60 g, due 
simply to cardiac and respiratory movements [1]. While ablation protocols vary between 
clinics, power settings are typically between 15-50W for AF ablations. In the current 
study, we demonstrated that, in order to maintain stable MAP recordings, an adequate CF 
must be applied; any deviation from an adequate CF will result in unstable MAP 
recordings. 
Clinically, electrograms have been used to evaluate lesion viability for decades, 
nevertheless both unipolar and bipolar voltage recordings have poorly correlated with CF 
[17]. However, recent studies have shown that the use of mini-electrodes to record 
electrograms during RF ablation improves lesion formation and can reduce complications 
[18, 19]. Further preliminary studies assessing lesion quality with MAP recordings have 
been previously conducted and are ongoing in our laboratory [20, 21]. 
The main findings of our study can be summarized as follows. First reproducible MAP 
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recordings require a mean catheter CF of 14.2 ± 2.9 g (epicardial) and 16.6 ± 2.5 g 
(endocardial). Second, the mean CF to elicit high quality MAP recordings is in the same 
range as the target CF for RF ablation, thus MAPs may act to supplement CF 
measurements and provide instantaneous insights relative to the device-tissue interface. 
Finally, due to the nature of a MAP, they can provide feedback on the conductivity and 
viability of the underlying tissue, and ultimately aid in both diagnosis and treatment of 
cardiac arrhythmias. 
Our study has several limitations. First, the fiber Braggs used to measure CF are delicate, 
limiting the operator’s ability to record from certain locations in and on the heart. 
Inserting the system into the reanimated swine heart required a precise hand; the slightest 
movement could offset the fiber from the tip of the catheter. In addition, we collected 
epicardial data only from the anterior surface of the ventricles (the most accessible from 
the pericardial cradle); future studies should consider collection from other epicardial 
locations. 
Conclusion 
An adequate CF of about 14.2 g (epicardial) and 16.6 g (endocardial) was required to 
reproducibly and continuously record MAPs. MAP recordings could mitigate the need for 
mechanical pressure sensors and use the recording platform of the ablation catheter to 
ensure contact, orientation, depth, and effectiveness of an ablation, without added 
mechanics and sensors to the tip, making the catheter smaller or adding room for other 
enhancements. 
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Preface 
Today, electrogram (EGM) amplitude is used as the primary method to evaluate tissue 
viability after the delivery of ablative energies. While EGM amplitude is sensitive to 
lesion formation, it is also sensitive to adipose tissue, catheter contact, and far-field 
influence. Monophasic action potentials are sensitive and specific to focal myocardial 
viability and are absent in the presence of adipose tissue and with insufficient contact 
force, making them a valuable tool for assessing lesion formation. 
For this research investigation, I was responsible for the initial experimental methods 
presented; however, this work was inspired by preliminary studies conducted by Dr. 
Mark Benscoter and myself. Due to the complex experimental protocol, I would not have 
been able to collect this data without the help of Kaileigh Rock, Angela Burgess, Tommy 
Valenzuela, Erik Gaasedelen, Alex Mattson, Lars Mattison, and Dr. Paul Iaizzo. I was 
responsible for the data and statistical analyses presented in this manuscript. 
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Summary 
Objective: Radiofrequency ablations are used to treat a variety of cardiac arrhythmias. 
The goal of this study was to evaluate the utility of recording monophasic action 
potentials (MAP) to determine lesion depths, surface areas, and volumes of epicardial 
radiofrequency ablations. 
Methods: Lesions were created on the epicardial surfaces of reanimated hearts in vitro 
using an irrigated, radiofrequency ablation catheter. Several power and duration 
combinations were utilized to create a range of lesion sizes. MAP amplitudes were 
measured at 0, 15, 30, 45, and 60 minutes post-ablation. Blinded observers provided 
qualitative analysis of the waveforms obtained 60 minutes post-ablation.  
Results: Baseline MAP amplitudes were 4.4±1.9 mV and were found to be significantly 
reduced in all lesion sets (p<0.05). There were no temporal changes in MAP amplitudes 
between any measure depths, surface areas, or volumes. At 60 minutes post-ablation, 
MAP amplitudes were significantly reduced for lesions between 1.00-1.99 mm deep 
compared to those 2.50-2.99, 3.00-4.00, and ≥4.00 mm deep (p<0.05). Lesion properties 
(depths, surface areas, and volumes) were inversely associated with recorded MAP 
amplitudes and MAP qualities.  
Conclusion: MAP waveforms can provide information on lesion sizes, which may 
increase a physician’s ability to predict lesion sizes during a radiofrequency ablation 
procedure. 
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Introduction 
Radiofrequency (RF) ablation is a common treatment for persistent atrial fibrillation 
(AF); however, pulmonary vein isolation (PVI) in such patients has often been met with 
limited success [1, 2, 3, 4]. Many groups have studied the addition of new ablation targets 
to eliminate these substrates through creating additional transmural lesions in locations, 
such as the left atrial roof, the mitral isthmus, and/or within the left atrial appendage [5, 
6].  
One could argue that often the limited success in ablation can be due to the 
reconnections, or re-activations within regions, which were thought to have been 
appropriately ablated [7, 8]. Recently it was reported that there are clinical utilities in 
recording monophasic action potentials (MAPs) for identifying either small lesion gaps, 
or a lack of transmurality [9]. Furthermore, studies have illustrated values in monitoring 
MAPs to elicit focal action potentials from unhealthy myocardium; e.g.  diseased, 
ablated, and/or infarcted. [10, 11, 12, 13].  
Previous studies have looked at the “field of view” and/or “depth of view” relative to 
MAP recordings, however this relationship is still largely undefined. The field of view is 
considered to be no less than the tip electrode diameter: yet, it has been shown that the 
angle between the tip, reference electrodes, and the myocardium plays a role, as well as 
electrode spacing [14]. These investigators concluded that MAP waveforms are likely 
generated from an area greater than the tip electrode size, but less than 5 mm in diameter 
[14, 15]. The exact depth of view to which MAP recordings can reach is even less clear, 
however studies have shown that MAPs likely originate from deeper layers of the 
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myocardium [14, 16, 17]. 
The primary objective of our current work was to evaluate the utilities of recording MAP 
waveforms in assessing relative lesion depths, surface areas, and/or volumes for induced 
epicardial RF ablations. Additionally, we sought to evaluate if temporal changes were 
present in MAP waveforms, recorded for a 1-hour lesion maturation period. 
Methods 
Yorkshire crossbreed swine were used in this study. The University of Minnesota 
Institutional Animal Care and Use Committee reviewed and approved the following 
procedures; all animals were humanely treated per Guide for the Care and Use of 
Laboratory Animals. 
Ablation procedure 
Hearts were excised and reanimated using previously described Visible Heart® 
methodologies [18]. A total of n=4 hearts were used for RF induced epicardial ablations 
(n=62) on the left ventricle. Ablations were delivered utilizing a 7Fr irrigated RF catheter 
with a 4 mm tip and using an RF generator (Atakr® Plus 990064, Medtronic LLC., 
Dublin, Ireland).  Normal saline was used for this irrigated catheter at 30 cc/min 
(CoolFlow™ Pump, Biosense Webster®, Irvine, CA). Energies were delivered at a range 
of power settings and durations, in order to create a variety of lesions sizes (depths and 
surface areas). Ablations were conducted with power control settings at 10 or 20 watts for 
either 15 or 30 seconds. The ablation catheter was oriented parallel to the myocardial 
surface and then shifted slightly during energy deliveries, so to reduce the incidences of 
steam pops. 
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Electrical recordings 
MAPs were recorded using MAP4 catheters (Medtronic LLC., Dublin, Ireland) at each 
ablation site prior to energy delivery, immediately post-ablation (0 minutes), and at time 
points of 15, 30, 45 and 60 minutes post-ablation. For all recordings, the MAP catheters 
were oriented perpendicular to the cardiac epicardial surfaces and placed in the same 
locations as were the therapeutic ablation catheters.  
MAPs were recorded and subsequently evaluated using a CardioLab EP Recording 
System (GE Healthcare, Chicago, IL). Note, that these MAP waveforms were derived 
from bipolar recordings between a contact (0.9 mm diameter) and nearby non-contacting 
electrode (1 mm ring spaced 2 mm proximal to the tip electrodes). Filter settings were set 
at 0.05 Hz and 1000 Hz. Signal amplitudes were measured from defined time points; 100 
msec after the beginning of the QRS complex as means to minimize the effects of far 
field potentials.  
The qualitative assessments of the MAP waveforms at the 60 minutes post-ablation time 
points were made by 3 blinded reviewers. Two reviewers were familiar with MAP 
recordings, while the third reviewer had a general knowledge of cardiac 
electrophysiology, but limited experience with assessing MAP waveforms. The reviewers 
studied the waveforms and were asked to place each signal into one of following 
categories: 1) “viable”, indicating normal MAP waveform characteristics, 2) “damaged”, 
indicating some level of MAP degradation, or 3) “ablated”, indicating the absence or 
extreme decays of the MAP waveform. 
Lesion assessment 
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In addition to the MAP waveform assessments, lesion sizes were also investigated. After 
the 60-minute time points, the ablated myocardium from each heart was placed in 
triphenyl tetrazolium chloride (TTC) stain, which was heated to 37° C prior to use. The 
tissue was submerged for 15 minutes, then removed and the lengths and widths of each 
lesion were measured. The lesions were then transected through the visible center and the 
tissue was re-submerged for an additional 15 minutes. The lesion depths were then 
measured. With these measurements, lesion surface areas were calculated using the 
equation for an ellipse. A given lesion volume was calculated based on a modified 
hemisphere equation; similar methods for RF lesion volume calculation are used in 
literature [19]. The methods for lesion measurements are shown in Figure 20. 
 
Figure 20. The top two panels of this image show lesions created using radiofrequency energy. In both 
images the scale bar is 5mm in length. The bottom images illustrate how lesions were measured, and the 
associated volume calculation. RF – radiofrequency, L – length, W – width, D – depth. 
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Statistics 
Continuous variables are presented as means ± standard deviations. Categorical variables 
are represented as percentages only. Statistical significance for continuous variables was 
evaluated using one-way analyses of variance (ANOVA) with applied Tukey’s honest 
significant difference (HSD) tests. A P value of less than 0.05 was considered statistically 
significant. 
Results 
Baseline MAP waveforms were collected prior to each ablation. Mean amplitude at 
baseline was 4.4±1.9 mV. The APD for baseline recordings was 336.5± 59.0 msec. 
Baseline heart rate was 92±9 bpm. Heart rate was stable over all days and time points, 
with mean rates at 90±8 bpm. 
Lesion depth 
MAP quality at 60 minutes post-ablation was compared directly to lesion depth. Lesions 
were separated into the following groups: 1.00-1.99 mm (n=10), 2.00-2.49 mm (n=15), 
2.50-2.99 mm (n=11), 3.00-3.99 mm (n=15), and ≥4.00 mm (n=11). Lesions which 
matured at 1 hour to between 1.00-1.99 mm deep were qualitatively assessed to be viable 
23% of the time, 46.7% were noted damaged, and 30.0% were seen as ablated (Figure 
21A). Between 2.00-2.49 mm, lesions were considered to be viable, damaged, and 
ablated in 13.3%, 33.3% and 53.3% of assessments respectively. Lesions over 2.50 mm 
(n=37) were noted to be viable only 3.6% of the time, and damaged 14.4%; these same 
regions were assessed to be ablated in 82.0% of measurements.  
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Waveform amplitudes were evaluated at 100 msec time points after the initial QRS 
deflections. MAP amplitudes for each lesion group are shown in Figure 21B and were 
grouped chronologically. There were no significant differences in MAP amplitudes for a 
given lesion depth at any time point. In other words, the MAP amplitudes immediately 
post-ablation, were not significantly different than those recorded at 60 minutes post-
ablation: or at any measured time points in-between. Amplitudes immediately post-
ablation and at 60 minutes were significantly greater for lesions 1.00-1.99 mm of depth, 
when compared to lesions with depths of either 2.50-2.99 mm, 3.00-3.99 mm, and ≥4.00 
mm. Lesions with depths of 1.00-1.99 mm elicited MAP amplitudes at the 30 and 45-
minute time points post-ablation, which were significantly greater than all other measured 
depths. No significant differences were observed between lesions with depths of 2.00-
2.49 mm, 2.50-2.99 mm, 3.00-3.99 mm, or ≥ 4.00mm.  
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Figure 21. A) Depiction of monophasic action potential (MAP) quality with respect to lesion depth in mm. 
For each lesion 3 response were recorded, 1 per reviewer. B) MAP Amplitude compared to lesion depth. 
Lesions between 1.00-1.99 mm deep were significantly different than deeper lesions. No differences were 
observed between time points for a given depth.  
 
Lesion surface area 
Lesions were grouped into approximately equal bins according to surface area for 
analyses: <85.0 mm2 (n=11), 85.0-99.9 mm2 (n=12), 100.0-129.9mm2 (n=13), 130.0-
174.9 mm2 (n=14), and ≥175 mm2 (n=12). MAP lesion quality was evaluated with 
respect to lesion surface area at 60 minutes post-ablation. Lesions less than 100 mm2 in 
surface area resulted in viable lesion assessments in 18.8% of cases, damaged in 37.7%, 
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and ablated in 43.5% of instances. Lesions ≥ 100 mm2 were noted to be viable in only 
5.1% of measurements and ablated in 80.3%. Additionally, with increasing depth (as 
grouped above) corresponded to a consistent increase in the number of measurements 
marked as dead, as well as a decrease in those marked as damaged (Figure 22A).  
Mean amplitudes for lesions in the aforementioned groups based on surface areas can are 
presented in Figure 22B. At the 15 minutes time points post-ablation, lesion with depths 
<85.0 mm2 had significantly higher measured amplitudes than those of ≥175.0 mm2. 
Additionally, at the same time point, lesion depths between 85.0-99.9 mm2 had 
significantly smaller amplitudes than those of 130.0-174.9 and ≥175.0 mm2. MAP 
recordings from induced lesions with <85.0 mm2 depths at both the 30 and 45 minutes 
time points post-ablation had significantly greater amplitude versus all lesion groups 
≥100.0 mm2. No significant differences were observed between any time point 
comparison for these assessed surface area groups. 
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Figure 22. A) Depiction of monophasic action potential (MAP) quality with respect to lesion surface area 
in mm2. For each lesion 3 response were recorded, 1 per reviewer. B) MAP Amplitude compared to lesion 
surface area. Significant differences were found between lesion groups, however there were no differences 
between time points for a given area.  
 
Lesion volume 
Lesion volume was also evaluated with respect to MAP quality at 60 minutes. Lesions 
were grouped into approximately equal bins according to volume: <30.0 mm3 (n=12), 
30.0-39.9 mm3 (n=12), 40-59. 9 mm3 (n=10), 60.0-99. 9 mm3 (n=15), and ≥100.0 mm3 
(n=13). Small lesions (those <30.00 mm3) were reported as viable in only 25.0% of 
instances, about the same number of times they were noted to be ablated (27.8%). 
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However, as was seen in the depth and surface area results, as the lesion volume 
increased the instances of viable and damaged tissues decreased and the waveforms were 
more often reported as being from ablated myocardium (Figure 23A). Lesion between 
60.0-99.9 mm3 were reported as viable only 4.4% of the time, damaged 8.9%, and ablated 
the remaining 86.7%. Overall lesions 40.0mm3 and larger resulted in 3.5% viable, 13.2% 
damaged and 8.3% ablated myocardium. 
Relative MAP amplitudes were also correlated with the induced lesion volumes (Figure 
23B). As with lesion depths and surface areas, there were no observed temporal changes 
in MAP amplitudes for the lesion volume groups analyzed. At the 15 minutes post-
ablation time points, the MAP amplitudes for lesion volumes <30.0 mm3 were 
significantly higher than those for volumes ≥100.0 mm3. When compared across the 30-
minute time points, for the MAP amplitude measurements, induce lesions with volumes 
<30.0 mm3 were significantly greater when compared to all other induced lesion 
volumes. Additionally, at 45 minutes post-ablation, the MAP amplitudes were larger for 
the <30.0 mm3 induced lesion volume group compared to those with volumes of 40.0-
59.9 mm3, 60.0-99.9 mm3, or ≥100.0 mm3. 
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Figure 23. A) Depiction of monophasic action potential (MAP) quality with respect to lesion volume in 
mm3. For each lesion 3 response were recorded, 1 per reviewer. B) MAP Amplitude compared to lesion 
volume. Significant differences were found between lesion groups, however there were no differences 
between time points for a given lesion volume. 
 
Discussion 
An ability to relatively assess the depths of generated myocardial lesions would be 
invaluable tool for optimizing the ablative treatments of cardiac arrhythmias. Here we 
evaluated the potential utility of recording MAPs as a means to approximate the 
underlying lesion depths, surface areas, and/or volumes; i.e., through both qualitative or 
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quantitative measures. Regardless of the induced lesion size, the relative MAP 
amplitudes, measured 100 msec after the beginning of the QRS, from known site of 
applied RF ablation were significantly reduced from the baseline amplitudes (p<0.05); 
indicating a strong sensitivity to identify lesion formation. Additionally, there were no 
significant differences associated with measured MAP amplitudes for up to an hour post-
ablation.  
Clinically, when utilizing RF ablation technologies for treating arrhythmia, 
electrophysiologists are continuously moving the catheters from one nearby cardiac 
location to another to create point-by-point lesions so to isolate the pulmonary veins from 
the left atrium. While technologies such as 3D mapping and navigation systems, 
fluoroscopy, and intracardiac echocardiography have enabled better visualizations of the 
relative catheter placements, it can be difficult as well as time consuming if one must 
backtrack so to ensure proper lesion formations (e.g., transmurality).  Therefore, potential 
benefits in procedural efficacy, could result from better knowledge of the relative lesion 
depth, which we have indicated here can be determined with MAPs assessments: i.e., 
immediately post-ablation, with the added abilities to distinguish between unablated 
tissues, as well as therapeutic locations which will become lesions of 1.00-1.99 mm, 
2.50-2.99 mm, 3.00-3.99 mm, and/or ≥4.00 mm depth for up to 1-hour post-ablation. 
When the relative MAP waveform quality was compared to the assessed lesion depths, 
there was an observed strong correlation in the number of recordings evaluated as ablated 
as lesion depths increased. In other words, the data we present here are supportive for 
evaluating relative lesion depths using the qualitative assessment of MAPs; this was 
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especially consistent for identifying lesions greater than 2.5 mm deep. When looking at 
the overall assessment of the lesions at the 60-minute time point, only 3.6% were 
assessed as viable while 96.4% were deemed damaged or ablated: e.g., of the lesions two 
marked as viable, one elicited a minimal lesion surface area which may have impacted 
MAP quality. 
Lesion depth also correlated significantly with quantified MAP amplitudes at the 60-
minute time points, with the subsequently determined lesion depths. Note, it still is 
unclear to what myocardial depths viable tissues can lead to the ability to record a MAP 
waveform [14, 16, 17]. However, in this study we demonstrated the abilities of MAPs to 
distinguish between lesions with depths of 1.00-1.99 mm compared to those of 2.50 mm 
or deeper: the deeper the lesion the more significant the decrease in MAP amplitude. 
Therefore, one could hypothesize based on these finding, that the bulk of the MAP 
waveforms recorded from healthy myocardium can be from cells between 2.0 and 2.5 
mm below the epicardial surfaces: these depths were not significantly different from the 
induced shallow lesions.  
Induced RF lesion volumes and lesion surface areas also correlated well with the 
estimated MAP waveform qualities. While lesion volumes were found to be directly 
impacted by overall lesion depths, lesion surface areas were in general independent of 
induced lesion depths; however, in general larger surface areas correlated with deeper 
lesions. While it is impossible to completely dissociate these parameters, a larger lesion 
set may enable a subsequent study evaluating lesions of a specific depth, but a variety of 
surface areas. This would allow the determinations of how MAP qualities might be 
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impacted based solely on depths or areas. 
There are a few limitations to note related to our study design. First, as mentioned 
previously, induced lesion depths, surface areas, and volumes were not independent from 
one another. For precise evaluations of lesion depths and surface areas, sub-sets of data 
could be analyzed with groups of like lesion depths and varying surface areas, or vice 
versa. Additionally, MAP waveform reviewers were allowed to interpret MAP quality 
based on their existing knowledge only; i.e., a set of parameters, or guidelines, may have 
resulted in more drastic differences between viable, ablated and damaged tissues; 
furthermore, the addition of more quality levels may increase the sensitivity of MAP 
quality as a tool. 
Conclusion 
There is a potential utility of recording cardiac MAPs as means to either quantitatively 
and qualitatively assess myocardial lesions created with RF ablative therapies. Relative 
MAP waveform qualities were found to be correlated with induced lesion depths, surface 
areas, and volumes. In addition, MAP amplitudes at 60 minutes post-ablation, decreased 
with induced lesion formation with depths greater than 1.00 mm; amplitudes were further 
decreased associated with lesions 2.50 mm and greater in depth. Finally, MAP 
amplitudes did not vary temporally for any measured lesion depths, surface areas, or 
volumes, indicating an ability to accurately assess RF induced lesions immediately post-
ablation. Overall, MAP waveforms could provide valuable information relative to 
induced RF lesion sizes, which should increase a clinician ability to estimate lesion sizes 
during an ablation procedure. 
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Section III: Novel catheter concepts for the diagnosis 
and treatment of tachycardias 
 
This final section focuses on developing catheter-based concepts which incorporate key 
experimental findings from the previous sections into novel catheters for the diagnosis 
and treatment of tachyarrhythmias. 
Radiofrequency ablation for persistent atrial fibrillation patients has proven less 
successful than ablation for paroxysmal AF patients; this is likely due to the existence of 
AF substrates outside of the pulmonary veins. In some cases, these substrates are 
identified through the recording of complex fractionated electrograms with mapping and 
ablation catheters. Due to the focal nature of monophasic action potential (MAP) 
recordings it was hypothesized that the incorporation of MAP recordings capabilities 
onto various mapping arrays may aid in the identification of AF substrates. 
A second catheter concept was tested for initial feasibility in the mapping of epicardial 
ventricular substrates. Currently, there are no catheters designed for epicardial mapping 
or ablation of ventricular tachycardias. In lieu of a dedicated device, physicians have 
made due with adapting endocardial technologies; however, these devices are limited in 
their ability to detect changes in repolarization properties and limit users to voltage 
mapping of the epicardial surface. The unique ability of MAPs to represent focal 
repolarization could aid in the identification of arrhythmic substrates, especially in 
channelopathies such as Brugada syndrome.  
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Preface 
Pulmonary vein isolation (PVI) is a primary method in the treatment and ablation of 
paroxysmal atrial fibrillation (AF). Current catheters used to measure PVI can be limited 
in their ability to distinguish far-field signals from pulmonary vein potentials. The use of 
monophasic action potential recording capabilities could reduce these far-field signals 
and provide more precise information relating to PVI. 
The prototypes presented in this work were conceptualized by Dr. Paul Iaizzo and 
myself. Prototyping was done in combination with the efforts of Julia Campion 
(Medtronic, Mounds View, MN), Carla Pfeiffer (Medtronic), and Gonzalo Martinez 
(Medtronic). Additionally, I was responsible for the preliminary testing of these devices 
with Dr. Mélèze Hocini (Centre Hospitalier Universitaire de Bordeaux, France) at the 
Visible Heart® Laboratory. 
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Summary 
Objective: High rates of pulmonary vein (PV) reconnection have been reported after 
ablation for atrial fibrillation, likely due to the reconnection of tissues which were 
stunned during the ablation. While several catheters exist for PV mapping, these catheters 
have limited sensitivity due to influences from far-field electrogram recordings, 
specifically in the left superior PV. Due to the highly focal nature of monophasic action 
potential (MAP) recordings, it was hypothesized that their incorporation onto circular 
mapping technologies could improve detection of PV isolation. 
Methods: Based on customer inputs and key design requirements, a PV ablation catheter 
was modified for MAP recording. This was done through the addition of spherical 
electrodes to the distal portion of the existing catheter design. 
Results: The placement of MAP recording electrodes limited the testing of the concept in 
the PVs; the electrodes extended distally into the vein, and not radially into the tissue. 
Epicardial signals were collected and indicated MAP recordings were possible with this 
catheter concept. 
Conclusion: MAP recordings with a circular mapping catheter are feasible, however 
further testing will need to be done. Future concepts should look modifying MAP 
electrode placement and incorporating a non-contact reference electrode for bipolar 
recordings. The combination of MAP recording capabilities onto a catheter which could 
also deliver ablative energy would be ideal for PVI assessment during AF ablation. 
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Introduction 
Pulmonary vein isolation (PVI) with radiofrequency (RF) and cryoablative energies has 
been shown to have similar procedural success rates in the treatment of atrial fibrillation 
(AF) [1, 2]. In patients with recurrence post AF ablation, PV reconnection rates have 
been reported as high as 91%, however other studies have reported high rates of durable 
PVI (no reconnection) in 75% of PVs [3-5]. These PV reconnections are often the result 
of tissues, which were stunned or damaged during the initial ablation, later regaining 
electrical activity, enabling conduction between the PVs and the left atrium (LA).  
During RF ablation, a circular mapping catheter (i.e. Lasso®, Biosense Webster, 
Diamond Bar, CA), is often used to assess PVI [7, 8]. During and after the delivery of 
point-by-point RF energy the Lasso® catheter is placed into the PV and electrical activity 
is evaluated. Another tool which can be used in evaluating PVI is the Achieve™ 
Mapping Catheter (Medtronic LLC., Dublin, Ireland). This mapping catheter is used in 
combination with the Arctic Front Advance™ Cryoballoon catheter (Medtronic). The 
Achieve™ catheter is placed into the PV and baseline PV electrical potentials are 
recorded. These potentials can then be monitored throughout the ablation to determine 
when PVI occurs. The time-to-isolation, or time from when the freeze begins until PV 
potentials disappear, has used to titrate the duration of energy application, leading to 
increased treatment success, reduced procedure times, and decreased adverse event rates 
[5, 8-10]. 
Clinical need 
Physicians need a tool which can accurately measure the electrical activity at the LA-PV 
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junction, in order to assess PVI. Current measurement systems have several limitations. 
The first limitation is in electrode size. Larger electrodes will integrate electrical activity 
over a larger tissue area, causing a prolonged effect on electrogram recordings. Smaller 
electrodes allow for more precise electrogram recordings. A second limitation is the 
inter-electrode spacing. The closer two electrodes are together, the less far-field signal 
will be recorded. This is especially apparent in the mapping of the left superior (LS) PV, 
which is in close proximity to the left atrial appendage (LAA). Often when mapping in 
the vein, the LAA signals may be pronounced and confound interpretation of PV 
potentials. Unless the disappearance of the vein potentials is evident during real-time 
ablation, it can be difficult to discern if the PV is isolated.  Monophasic action potential 
(MAP) recordings may reduce the impact of far-field signals and could provide 
immediate feedback on the viability of the underlying myocardium. 
Key design requirements 
The key design inputs (Table 6) are indicative of system components that would be 
required for a catheter designed to record MAPs for the assessment of PVI. 
Table 6. Key design requirements for a circular mapping catheter 
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Pugh chart 
Based on the above design inputs and the customers’ needs a Pugh chart was created to 
determine a catheter concept to move forward with (Table 7). The pulmonary vein 
ablation catheter (PVAC) based design will be explored further. 
Table 7. Pugh chart for a circular mapping catheter 
 
Initial concepts and prototypes 
 In this concept a PVAC catheter was modified. To enable the recording of MAPs, 
rounded spheres were added to each existing base electrode. To do this, on each electrode 
a small scratch/defect was created in the surface most distal to the catheter handle. A 
small amount of silver solder was then added onto the existing electrode, taking care not 
to melt the surrounding catheter components (Figure 24). The solder spheres were 
approximately 1 mm in diameter. Once the rounded electrode was created, the base 
electrode was covered in a UV curable polymer to allow electrical recordings from only 
the rounded portions (Figure 25A and B). 
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Figure 24. A pulmonary vein ablation catheter electrode ring was modified through the addition of small 
balls of conductive material to the existing base electrodes. 
 
 
Figure 25. A pulmonary vein ablation catheter electrode was masked with a UV polymer to allow electrical recording 
from only the spherical part of the electrode. 
 
Preliminary testing and physician feedback 
This concept was tested at the Visible Heart® Laboratory with Dr. Mélèze Hocini. 
Initially the catheter was placed into the left atrium through a cannulated PV. While the 
catheter was easily manipulated within the atrium, there was not sufficient interaction 
between the MAP electrodes and the myocardium in the PVs. Because of the dome 
placement on the distal portion of the electrodes, the domes protruded distally into the 
vein, rather than radially into the tissue. 
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To evaluate the feasibility of MAP recordings with this concept, the catheter was also 
placed against the epicardial surface of a reanimated swine heart. The catheter was 
pressed against the left ventricular epicardium. Unipolar waveforms were recorded from 
each electrode with respect to Wilson’s Central Terminal (WCT). When force was 
applied to the catheter shaft some depolarization was seen, however the force was not 
evenly distributed to each electrode. Additionally, force was manually applied to the 
entire ring, causing all electrodes to press into the myocardium. This caused waveforms 
reminiscent of MAPs to be visualized on some unipolar channels (Figure 26). 
 
Figure 26. Shown here are representative waveforms from the prototyped catheter. These channels are 
representative of the unipolar MAP recordings. The white arrows indicate representative monophasic 
action potential waveforms. Amplitudes for these waveforms range between 1-3mV. 
 
Future directions 
With this initial prototype we were able to obtain valuable feedback for the development 
of future devices. First, the prototype catheter did not have a non-contact reference 
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electrode for bipolar MAP recordings. While unipolar MAPs are beneficial, they lack the 
focal specificity that is recorded with near-field bipolar recordings. While bipolar 
waveforms can be recorded between contacting electrodes this could lead to the 
misinterpretation of data. When two electrodes are both causing focal depolarization, it is 
unclear what tissue is responsible for the resultant MAP waveform. It is hypothesized that 
if E1 and E2 were both depolarizing electrodes, that then the direction of the MAP 
waveform (positive versus negative) would indicate which electrode has better contact. 
Secondly, the structure of the catheter was not conducive to MAP recording capabilities. 
The MAP electrodes will need to be angled more radially in order to improve tissue 
contact. Additionally, the catheter may not provide enough radially force to cause focal 
depolarizations. Future devices must incorporate the changes in MAP electrode 
orientation to further evaluate feasibility. 
Finally, it was discovered upon the completion of prototype testing that the UV curable 
polymer, used to mask the base electrodes, was not compatible with the Krebs-Henseleit 
buffer used in these studies. It is unclear at what point in the experiments the polymer 
began to disintegrate. It is clear though, that without the masking of the base electrodes, 
focal MAP waveform quality will be diminished with far-field electrogram recordings. 
Future prototypes must look into alternative masking agents, or the creation of a custom 
catheter with only dome like electrodes, eliminating the need for a masking agent. 
In conclusion, the recording of MAPs for PVI assessment is possible, however further 
development of electrode concepts is needed. Future concepts should look at adjusting 
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the placement of the spherical electrodes so to optimize the electrode-tissue interface. A 
non-contact reference electrode will also need to be added for proper evaluation of 
bipolar MAPs. Additionally, the spherical electrodes must be the only active recording 
electrodes, in other words if an existing electrode is modified the base electrode must 
remain electrically isolated from the myocardium. The combination of MAP recording 
capabilities onto a catheter which could also deliver ablative energy would be ideal for 
PVI assessment during the ablation of AF. 
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Preface 
Pulmonary vein isolation (PVI) is a primary method in the treatment and ablation of 
paroxysmal atrial fibrillation (AF); however, PVI has been less success in patients with 
persistent and long-standing persistent AF, likely due to atrial remodeling and the 
existence of AF triggers outside of the pulmonary veins. The use of monophasic action 
potential recording capabilities could reduce, or even eliminate, the influence of far-field 
signals, resulting in more precise identification of AF substrates. 
The prototypes presented in this work were conceptualized by Dr. Paul Iaizzo and 
myself. Prototyping was done in combination with the efforts of Julia Campion 
(Medtronic, Mounds View, MN), Carla Pfeiffer (Medtronic), and Gonzalo Martinez 
(Medtronic). Additionally, I was responsible for the preliminary testing of these devices 
with Dr. Boaz Avitall (University of Illinois, Chicago, Illinois), Dr. Michael Franz (VA 
Hospital, Washington D.C.), and Dr. Mélèze Hocini (Centre Hospitalier Universitaire de 
Bordeaux, France) at the Visible Heart® Laboratory. 
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Summary 
Objective: Pulmonary vein (PV) ablation for patients with persistent atrial fibrillation 
(AF) has been less successful than for patients with paroxysmal AF, presumably because 
of triggers originating away from the PVs.  Efforts have been made to increase ablation 
effectiveness by targeting non-PV locations, including arrhythmogenic 
electrophysiological sources. Due to the highly focal nature of monophasic action 
potential (MAP) recordings, it was hypothesized that their incorporation onto mapping 
arrays could improve the detection of these arrhythmogenic substrates. 
Methods: Based on customer inputs and key design requirements, a multiarray ablation 
catheter was modified for MAP recordings. This was done through the addition of 
spherical electrodes to the distal portion of the existing catheter design. 
Results: Unipolar MAP waveforms were recorded from endocardial and epicardial 
locations on the atria and ventricles. Sufficient contact force required for MAP recordings 
was not obtained in some cases. 
Conclusion: MAP recordings with a multiarray mapping catheter are possible, however 
future concepts will need to optimize the contact force generated by the recording 
electrodes and included a non-contact reference for bipolar recordings. The combination 
of ablative energy would be ideal for the subsequent ablation of identified arrhythmic 
substrates. 
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Introduction 
Atrial fibrillation (AF) is defined by irregularly irregular activation of the left and right 
atria. Isolation of the pulmonary veins (PVs), using radiofrequency or cryogenic ablation, 
is a common practice that has been reported to have a high rate of treatment success. 
Using a pulmonary vein ablation catheter (Medtronic, Dublin, Ireland) success rates were 
reported as high as 83% in paroxysmal AF [1]. However, treatment success is lower for 
patients with persistent AF, presumably because of AF triggers originating away from the 
PVs.  As a result, efforts have been made to increase ablation effectiveness by targeting 
non-PV locations, including ablation of anatomical structures such as the left atrial 
appendage as well as arrhythmogenic electrophysiological sources, such as rotors and 
complex fractionated electrograms (CFAEs) [2, 3]. These electrophysiological substrates 
can be identified through intracardiac mapping and have been implicated in the initiation 
and maintenance of AF. As a result, novel approaches may be required to facilitate the 
identification and localization of non-PV targets for ablation [2-5]. 
Catheter concepts have been developed specifically to map and identify these 
electrophysiological sources. One catheter developed for the identification of CFAEs is 
the Multiarray Ablation Catheter (MAAC) (Medtronic). The MAAC is a cross-shaped 
array with 1 pair of electrodes on each of the 4 catheter arms [6, 7]. The electrodes are 2 
mm long with 2 mm inter-electrode spacing; this configuration allows for 4 bipolar, or 8-
unipolar recordings.  This catheter is used for mapping and ablation of CFAEs, 
specifically those originating from the posterior, superior, and anterior aspects of the left 
atrium. Another multiarray catheter is the PentaRay® Catheter (Biosense Webster, 
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Diamond Bar, CA). The PentaRay® catheter is a 5-spline catheter with 4, 1 mm 
electrodes on each spline. There are several versions of this catheter with different inter-
electrode spacing configuration (either a 4-4-4 mm spacing configuration, or a 2-6-2 mm 
configuration). The catheter can be used for electroanatomical mapping in conjunction 
with a navigation system to provide mapping and activation data for all four chambers of 
the heart [8, 9]. 
Clinical need 
Physicians need a tool which can record detailed electrical signals from a large number of 
atrial locations. Due to the need to cover a large amount of substrate with each catheter 
placement, a catheter with an array of electrodes is ideal. The catheter must also be able 
to distinguish slight changes in activation timing and patterns between the electrodes; 
minimizing far-field input via small inter-electrode spacing will be key in assessing 
activation sequence and local electrical activity accurately. It is hypothesized that CFAEs 
will exhibit unique monophasic action potential (MAP) waveforms and that activation 
patterns will be easily identifiable with MAP recordings.  The CFAEs may then be 
targeted for ablation, potentially increasing the ablation effectiveness for AF treatment.   
Key design requirements 
The key design inputs (Table 8) are indicative of system components that would be 
required for feasibility testing of a catheter designed to record monophasic action 
potentials, the identification of CFAEs, and other non-PV arrhythmic substrate in the left 
and right atria. 
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Table 8. Key design requirements for a multiarray mapping catheter 
 
Pugh chart 
Based on the above design inputs and the customers’ needs a Pugh chart was created to 
determine a catheter concept to move forward with (Table 9). Based on the weighted 
design criteria a MAAC based catheter will be explored. 
Table 9. Pugh chart for a multiarray mapping catheter 
 
Initial concepts and prototypes 
In this concept a MAAC catheter was modified. To enable the recording of MAPs 
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rounded spheres were added to each existing base electrode. To do this, on each electrode 
a small scratch/defect was created in the surface most distal to the catheter handle. A 
small amount of gold-based solder was then added onto the existing electrode, taking care 
not to melt the surrounding catheter components (Figure 27). Once the rounded electrode 
was created, the base electrode was covered in a UV curable polymer to allow electrical 
recording from only the rounded portion. Additionally, a wire was run the length of the 
catheter and placed in the center of the electrode array, proximal to the tip electrodes 
(Figure 28). This wire was to serve as a non-contact reference for bipolar MAP 
recordings. A second prototype design was made using the above methods, however the 
electrode array was modified to be a 4 electrode configuration versus an 8 electrode 
configuration (Figure 29). 
 
Figure 27. Electrodes from a multi-array ablation catheter were modified through the addition of small 
spherical electrodes to existing base electrodes. The sphere sizes were relatively consistent, however in 
many cases the surrounding electrical and structural components were compromised. 
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Figure 28. A multi-array ablation catheter was modified for bipolar monophasic action potential 
recordings. Spheres were added to each existing electrode and the base was coated in a UV curable 
polymer. A wire was also added to the center of the array to serve as a non-contact reference electrode. 
 
 
Figure 29. The electrodes array from a multi-array ablation catheter was modified such that there were 
only 4 electrodes instead of 8 to increase contact force. 
 
Preliminary testing and physician feedback 
This concept was tested at the Visible Heart® Laboratory with Drs. Boaz Avitall, 
Michael Franz, and Mélèze Hocini. Unipolar signals were recorded from each tip 
electrode to Wilson’s Central Terminal. In cases where a non-contact reference electrode 
was used, bipolar signals were recorded between a tip electrode and the reference 
electrode. 
During in situ testing the 8-electrode catheter was placed on the epicardial surface of an 
in situ swine heart, following a median sternotomy. For epicardial recordings a large 
amount of contact force was necessary to create MAP waveforms. However, when focal 
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depolarization was successful, unipolar MAP waveforms were recorded from the 
epicardial right ventricular outflow tract (Figure 30).  Additionally, MAP recordings were 
obtained from the epicardial lateral wall of the left ventricle in situ (Figure 31). A second 
8-electrode with silver solder, instead of gold, was also used for epicardial recordings. 
The silver catheter experienced significantly more drift in recordings; making it virtually 
impossible to record stable signals (data not shown). 
 
Figure 30. Unipolar monophasic action potentials were recorded from the epicardial surface of the right 
ventricular outflow tract of a swine heart in situ. The white arrow indicates far-field influence in the 
recording, due to a lack of a close-bipolar reference electrode. 
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Figure 31. Unipolar monophasic action potentials were recorded from the epicardial surface of the lateral 
left ventricle of a swine heart in situ. The white arrow indicates far-field influence in the recording, due to 
a lack of a close-bipolar reference electrode 
Prototype testing was also conducted on reanimated swine hearts. MAPs were collected 
from both the left atrium and left ventricle. In the left atrium, the catheter was 
manipulated to the mitral annulus. Unipolar MAP waveforms were elicited when 
sufficient force was applied to the myocardium (Figure 32). Additionally, when the MAP 
catheter was advanced into the left ventricular apex MAPs were also recorded. 
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Figure 32. Unipolar monophasic action potentials were recorded from the lateral wall of the left atrium, 
near the mitral isthmus, in a reanimated swine heart. Amplitudes were between 2-4 mV. 
 
Future directions 
These prototype catheters demonstrated the ability of a multiarray catheter to elicit MAP 
recordings. However, during these studies there were several key learnings which will 
help improve future prototypes.  
First is the optimization of the electrodes. In these prototypes either silver or gold-based 
solders were used.  It was realized that material selection, even for feasibility studies, was 
crucial, as it dramatically impacted in the quality of the MAP waveforms. Additionally, 
the placement of the reference electrode will need to be optimized. For epicardial 
recordings the reference was a wire attached to the catheter shaft; the wire was then 
electrically connected to the tip electrodes with a conductive gel. Ideally there would be a 
unique reference just proximal to each tip electrode. One possible solution is to modify 
the base electrode such that the cooling fin which extends away from the tip could be 
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isolated and used as the reference. 
Feedback from physicians also brought into question the size and shape of the electrode 
array and questioned the overall utility. With the 8 electrode array it was difficult to 
induce sufficient depolarization with the electrodes to record MAPs. While the 4 
electrode configuration seemed to provide more mechanical push, the array was not 
stable enough to be tested adequately.  Large electrode arrays can often be difficult to 
manipulate endocardially, and as pointed out by one physician, may not reach into small 
gaps between pectinate structures.  
Overall a multiarray MAP recording concept demonstrated an ability to record both 
endocardial and epicardial MAPs from the atria and ventricles. Future concepts will need 
to optimize the MAP electrodes through modifying the base electrode such that a 
spherical tip can depolarize the myocardium, while the cooling-fin can serve as a non-
contacting reference electrode. Additionally, various array configurations should be 
evaluated for mapping endocardial atrial anatomies. The combination of MAP recording 
capabilities onto a catheter which could also deliver ablative energy would be ideal for 
the identification, and subsequent ablation, of CFAEs and other endocardial arrhythmic 
substrates. 
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Preface 
Ventricular tachyarrhythmias are responsible for over 325,000 deaths in the United States 
each year; many of these arrhythmias originate from the epicardial surface of the heart. 
To date there are no catheters designed for the mapping and ablation of epicardial 
ventricular arrhythmias. The recording of monophasic action potentials could allow for 
the unique visualization of repolarization patterns, which would be otherwise impossible 
with traditional electrogram recordings. 
The prototypes presented in this work were conceptualized by Dr. Paul Iaizzo and myself 
and have been submitted as a US patent application (US15441501). I was responsible for 
prototype construction, and for the preliminary testing of these devices with Dr. Boaz 
Avitall (University of Illinois, Chicago, Illinois) and Dr. Michael Franz (VA Hospital, 
Washington D.C.) at the Visible Heart® Laboratory. 
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Summary 
Objective: Ventricular tachycardias, such as channelopathies like Brugada Syndrome, 
are often caused by abnormal substrate on the epicardial surface. However, there are no 
devices available today that were designed for epicardial mapping/ablation of the 
ventricles. Here we created a custom mapping catheter, with monophasic action potential 
(MAP) recording capabilities, specifically for the identification of abnormal epicardial 
substrates. 
Methods: Initially a custom balloon concept was created, utilizing two inner balloons for 
inflation and generation of catheter contact force, and an outer balloon as a structure on 
which MAP recording electrodes could be placed. A second concept, based off a surgical 
paddle lead, was also developed through the addition of spherical MAP recording 
electrodes. 
Results: When tested, the initial balloon concept was much too large in comparison to 
the anterior surface of the heart. Additionally, the catheter was not able to maintain stable 
contact with the epicardium for MAP recordings. The second concept was able to elicit 
MAP recording from the epicardial surface of the right ventricular outflow tract, a 
common target in epicardial ablations. 
Conclusion: Epicardial MAP recordings for the identification of irregular ventricular 
substrates may be feasible. Array size and shape, as well as electrode placement will be 
critical inputs to elicit high quality MAPs. In combination with ablative energies, this 
type of system could improve the efficacy of epicardial ventricular ablations. 
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Introduction 
Sudden cardiac death (SCD) from ventricular tachycardias (VT) account for more than 
325,000 deaths in the United States each year [1-3].  In individuals under the age of 40, 
early repolarization diseases such as Brugada syndrome, Wolff-Parkinson-White 
syndrome, and Long-QT syndrome are often thought to account for many cases of SCD 
[2, 4]. Brugada syndrome is identified by an elevation in the ST-segment on the right 
precordial leads [5, 6]. In 2011 is was shown that Brugada syndrome was associated with 
delayed depolarization in the epicardial surface of the right ventricular outflow tract, thus 
making this a target for ablations [7, 8]. Monophasic action potential (MAP) recordings 
could be able to uniquely identify these altered repolarization pathways with higher 
fidelity than typical electrogram recordings. 
There are no devices available today that were designed for epicardial mapping/ablation 
of the ventricles; however endocardial systems have been used in lieu of a custom 
epicardial tool. One common system used in the epicardial mapping of VT substrates is 
the Carto® EP mapping system (Biosense Webster, Diamond Bar, CA) [7-9]. The 
mapping catheter is often the same catheter used in the ablation, such as the 
ThermoCool® SmartTouch® catheter (Biosense Webster). In these procedures, access to 
the epicardial surface is gained through a pericardial access point. The catheter is then 
used to record electrogram voltages across the desired area. The voltages are then 
separated into dense scar and border zones, defined by amplitudes <0.5 mV and < 1.5 
mV respectively. Additionally, abnormal electrograms can be tagged on the mapping 
system as those meeting some existing criteria: e.g. wide duration (<80 msec), multiple 
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electrogram peaks (>3), or those containing delayed components [9]. After identification 
of the abnormal and/or border regions epicardial ablations are performed to eliminate 
irregularities. 
Clinical need 
Physicians need a tool with which they can accurately identify the origin of epicardial 
based VTs. The catheter must be able to access the right and left ventricular epicardium 
through minimally invasive means such as substernal pericardial access point. The 
catheter must be able to record from all regions of the ventricular epicardium including 
the diaphragmatic surface. Additionally, the catheter should be composed of an array of 
electrodes, to identify regions of earliest activation, as well as the presence of rotors and 
abnormal repolarization patterns. Finally, the catheter should be able to distinguish 
regions of low electrogram voltage from epicardial fat or coronary vasculature. 
Key design requirements 
The key design inputs listed below (Table 10) are indicative of system components that 
would be required for feasibility testing of an epicardial monophasic action potential 
recording catheter for the identification of ventricular arrhythmic substrates. 
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Table 10. Key design requirements for a pericardial mapping array 
 
Pugh chart 
Based on the design inputs and the customers’ needs a Pugh chart was created to 
determine a catheter concept to move forward with (Table 11). Based on the weighted 
design criteria a custom balloon catheter was selected. 
Table 11. Pugh chart for a pericardial mapping catheter 
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Initial concepts and prototypes 
It was determined after an extensive patent search that no previous IP was present in this 
area. A patent application was filed, and approval is currently pending approval 
(US15441501). The illustrations shown are from this patent application.  
A prototype balloon catheter was designed. The catheter was composed of 3 main parts: 
MAP recording electrodes, an outer pocket, and 2 inner balloons (Figure 33 and 34). The 
electrodes were round spheres attached to thin, but rigid, support wires. The outer balloon 
was sized such that the 8 electrodes could be equally spaced in two columns. 
Additionally, the outer pocket was made large enough to allow for 2 cylindrical balloons 
to fit side by side. The inner balloons, when inflated, provided the contact force between 
MAP electrodes and the epicardium required for MAP recordings (using counter pressure 
from the pericardium).   
 
Figure 33. The prototype concept and patent renderings (US15441501) for the pericardial mapping 
balloon for monophasic action potential recording on the epicardial surface of the ventricles. The left two 
images show the balloon from the bottom (surface contacting the myocardium) and the right two images 
show the balloon from the top (side contacting the pericardium). The main catheter components are 
labeled in the patent drawings: 38 – outer structural balloon/pocket, 40 – inner balloons used for inflation 
and generation of contact force, and 44 – spherical electrodes for monophasic action potential recording. 
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Figure 34. The prototype concept and patent renderings (US15441501) for the pericardial mapping 
balloon for monophasic action potential recording on the epicardial surface of the ventricles. The balloon 
is shown from the side and the electrode can be seen protruding from the surface. The main catheter 
components are labeled in the patent drawings: 38 – outer structural balloon/pocket (not labeled in this 
drawing), 40 – inner balloons used for inflation and generation of contact force, and 44 – spherical 
electrodes for monophasic action potential recording. 
 
Preliminary testing and physician feedback 
This prototype concept was tested, and feedback was obtained from two leading 
electrophysiologic experts: Dr. Boaz Avitall and Dr. Michael Franz. In prototype testing 
only unipolar MAPs were recorded, using Wilson’s Central Terminal as a reference. A 
median sternotomy was performed, and the catheter was inserted into the pericardial 
space through a small opening. It was immediately clear that the overall size was much 
too large with respect to the surface of the heart (Figure 35). Additionally, the electrodes 
were unable to engage in a fixed location on the myocardium, moving constantly with the 
cardiac and respiratory cycles, and were unable to elicit MAP waveforms.   
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Figure 35. The prototype device was inserted into the pericardial space. The dotted outline indicates the 
cardiac silhouette, while the solid white outline is around the prototype. This concept was deemed too large 
for the intended purpose. 
 
Second generation concepts and prototypes 
Upon feedback from the physicians it was clear that there was a need for an epicardial 
mapping array, however the initial balloon prototype needed much improvement. Our 
second-generation concept was designed off a neurostimulation surgical paddle lead. The 
flat circular electrodes acted as a base on which spherical MAP electrodes could be added 
(Figure 36). Additionally, the flat back of the lead was modified into a rounded dome to 
provide the mechanical force needed for MAP recordings, provided by the inner balloons 
in the previous concept. 
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Figure 36. second generation pericardial mapping prototype was constructed using a neurostimulation 
surgical paddle lead. The lead was modified with spherical electrodes and a rounded backing to increase 
the force on the epicardial surface. 
 
Second generation testing and physician feedback 
The second pericardial mapping prototype was tested on a swine heart after a median 
sternotomy. The device was inserted through a small opening in the pericardium and 
placed on the anterior surface of the right ventricular outflow tract. A wire was placed on 
the proximal endo of the device (on the back of the lead) to act as a non-contact reference 
for bipolar MAP recordings. In comparison to the initial balloon concept, this second 
device was significantly smaller and easier to manipulate in the pericardial space (Figure 
37). Additionally, preliminary results demonstrated the ability to record MAP waveforms 
with electrodes in this configuration (Figure 38). It should be noted however, that the 
electrodes closest to the reference (electrode 3 and 4) were the only electrodes which 
elicited bipolar MAP recordings. 
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Figure 37. The surgical lead based prototype was inserted into the pericardial space. The dotted outline 
indicates the cardiac silhouette, while the solid white outline is around the prototype.  
 
 
Figure 38. A second generation pericardial mapping prototype was used on the right ventricular 
epicardium of an in situ swine heart. Waveforms representative of monophasic action potentials were 
recorded on bipolar pairs between electrodes 3 and 4 and a non-contact reference electrode. 
 
Conclusion 
The area of pericardial/epicardial mapping is one that is vastly underdeveloped. As more 
epicardial ablations for VTs, like Brugada syndrome, are being performed the need for a 
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tool designed specifically for epicardial mapping is increasing. While the concepts shown 
here are promising, there is still much that can be done to improve their ability to detect 
and diagnoses these arrhythmias. 
One of the major hurdles in epicardial mapping and ablation is the presence of epicardial 
fat. These initial feasibility studies were conducted on swine hearts, which have 
significantly less epicardial fat than human hearts. When electrograms are recorded from 
regions with high epicardial fat, their amplitude is reduced, which may be misinterpreted 
as non-viable, or scarred tissue. The use of MAP recording capabilities would enable 
better distinguish between these regions. 
In order for the elicitation of high-quality, focal MAP recordings, there must be a near-by 
non-contacting reference electrode. In these concepts bipolar MAPs were only elicited 
from the electrodes nearest the reference. A more central, or second reference could 
improve MAP recording capabilities. Additionally, the single row electrode arrangement 
used in the second generation concept is less conducive to activation mapping and the 
identification of rotors. A 2-by-2 button like array may provide added benefit in the 
identification of irregular ventricular substrate. 
In conclusion, epicardial MAP recordings for the identification of irregular ventricular 
substrates may be feasible. Array size and shape will be critical inputs for the ability to 
record MAPs from a large range of epicardial regions, both anterior and posterior. 
Additionally, it will be important to optimize the electrode-tissue interface, so that stable 
recordings can collected. In combination with ablative energies, such as radiofrequency 
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and/or cryoablation, this type of system could greatly improve the efficacy of epicardial 
ventricular ablations. 
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epicardial and endocardial surfaces of porcine hearts 
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Objective: Monophasic Action Potentials (MAPs) are electrical signals that represent the 
focal depolarizations and repolarizations of cardiac myocytes. The detection of MAPs via 
applied catheters may aid in determining both characteristic waveforms as well as the 
relative viability of the underlying cardiac tissue. For example, such detection would be 
beneficial in cases of atrial fibrillation, where ablative therapies are used to kill the cells 
triggering the arrhythmia. By recording MAPs at the trigger site post-ablation, the 
success of the treatment can be assessed immediately, and corrected if necessary. The 
purpose of the present study was to collect and compare signature endocardial and 
epicardial MAPs from isolated swine hearts.  
Methods: Hearts from swine were re-animated using previously described Visible 
Heart® methodologies: each heart was functioning in a normal sinus rhythm. Modified 7 
Fr mapping catheters, with 4 ball electrodes and 2 ring electrodes each, were placed upon 
the epicardial surface while another was inserted into the heart. The catheters were 
arranged such that both recorded from the same approximate anatomical location. This 
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was verified through internal imaging with an endoscope and an overhead camera (and in 
some cases fluoroscopy). Endocardial and epicardial MAPs, along with the ECG, were 
recorded using a multichannel recorder. 
 
Figure 1. A) Data collection from an endocardial catheter in the right atrial appendage of a reanimated 
swine heart. B) Endocardial and epicardial monophasic action potential recordings from the right 
ventricular apex. 
Results: MAPs were recorded from both atrial and ventricular locations on the right side 
of the heart. Preliminary results show that the profile of MAPs when recorded in the right 
ventricular outflow tract (RVOT) differ for epicardial and endocardial sites.  When 
comparing recordings taken in the right ventricle however, the profile of epicardial and 
endocardial MAPs were nearly identical. 
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Table 1. Monophasic action potential properties from endocardial and epicardial comparisons. 
 
Conclusion: In cases of atrial fibrillation an ablation may be performed either 
epicardially or endocardially on the myocardium: attempting to make induced lesions 
transmural. The detection of Monophasic Action Potentials using a MAPs catheter can be 
used to determine the relative, acute, viability of cardiac tissue in a specific area, which 
can lead to a higher rate of success for the treatment of atrial fibrillation. 
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Objective: Monophasic Action Potentials (MAPs) are electrical signals that represent the 
focal depolarizations and repolarizations of cardiac myocytes. The detection of MAPs via 
applied catheters may aid in determining both characteristic waveforms as well as the 
electrical activity of the underlying cardiac tissue. Recording MAPs in the right and left 
atria simultaneously can lead to a better understand the depolarization and repolarization 
times. In addition, we can use this methodology to deduce these values change during 
arrhythmias. The purpose of the present study was to collect and compare MAPs 
recorded from the left and right atria in isolated swine hearts.  
Methods: Hearts from swine were re-animated using previously described Visible 
Heart® methodologies: each heart was functioning in a normal sinus rhythm. Modified 7 
Fr mapping catheters, with 4 ball electrodes and 2 ring electrodes each, were placed upon 
the endocardial surface of the right and left atria. The locations of the catheters were 
verified through internal imaging with endoscopes and fluoroscopy. Right and left atrial 
MAPs, along with the ECG, were recorded using a multichannel recorder. 
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Figure 1. The left and right atrium were divided into 6 distinct zones where the right atrium consisted of 
zones A-F and the left atrium consisted of zones G-L. Images are modified from the Atlas of Human 
Cardiac Anatomy. 
 
Results: Preliminary results show the activation times (AT) for the right atrium were 
around 70msec shorter than those of the left atrium (n = 10).  When looking at the time 
taken to repolarize by 90% (APD90) the Right Atrium depolarized slightly slower, taking 
about 9 msec longer on average. These two results combined lead to the right atrium 
having shorter repolarization time than the left atrium by about 52 msec (AT + APD90).  
Arrhythmias were induced in both the right and left atria and the relative 
activation/repolarizations were recorded. 
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Figure 2. Comparison of half maximum duration for monophasic action potentials recorded in the left 
(Zones G and J) and right (Zones B, C, E, and F) atria. The half maximum duration for Zone E was 
significantly longer than that of Zone G when compared using ANOVA and Tukey HSD (p < 0.05). 
 
Conclusion: The assessment of Monophasic Action Potentials simultaneously recorded 
from the myocardium in both the right and left atria, can lead to a better understanding of 
the conduction pathways and the origin of arrhythmias. Using this approach, we can 
begin to better understand the specifics behind the changes in right and left atrial 
contractions, and how they are altered during arrhythmias. 
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Background 
Cardiac monophasic action potentials (MAPs) are electrical signals that represent the 
focal depolarizations and repolarizations of the underlying cardiac myocytes [1]. These 
signals are typically synchronized with cardiac function, and thus can record localized 
waveforms that can be used to determine activation timings and patterns, conduction 
velocities, and/or origins of arrhythmic behaviors [2-4]. The analysis of MAPs has also 
been used as means of identifying catheter contact forces and lesion borders post-ablation 
[5]. 
When designing and developing medical devices the ability to study device functionality 
in an ex-vivo setting can be crucial. Nevertheless, it is important that the studied 
anatomies and functionality be as close to that of a human in-vivo as possible. For over a 
decade our laboratory has utilized an isolated four-chamber working large mammalian 
heart model (the Visible Heart® methodology) to study the device-tissue interface [6]. 
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This experimental approach utilizes a modified Krebs-Henseleit perfusate which is clear, 
thus allowing for direct visualization using endoscopes. 
Additionally, within our laboratory we have the unique opportunity to study device 
responses within a given heart both in-situ, as well as in-vitro. The purpose of the present 
study is to illustrate how the Visible Heart® methodologies can be best utilized to assess 
the design and relative functionalities of MAP recording catheters. 
Methods 
Swine weighing between 70 and 80 kg were used in these studies. Animals were initially 
anesthetized with 500 mg of Telazol and 500 mg of Methohexital. Animals were then 
intubated and maintained in a plane of deep anesthesia (1.5% isoflurane). MAPs were 
then recorded in-situ from both the endocardial and epicardial surfaces of the heart. To 
record signals endocardially on the left side a transseptal puncture had to be performed. 
Catheter locations were verified through either direct visualization for epicardial catheters 
or fluoroscopy (Ziehm Vision R) for endocardial locations, as can be seen in Figure 1.  
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Figure 1. Endocardial catheters were visualized with fluoroscopy (left), while epicardial catheters could be 
directly visualized. 
 
These animals’ hearts were then stopped using a standard cardioplegia protocol into the 
aorta and then excised. Each heart was then removed and cannulated for re-animation, 
using previously described Visible Heart® methodologies [6]. Cardiac hemodynamic 
function was maintained while the various MAP recording catheters were again placed 
either epicardially or endocardially with using direct visualization via video endoscopes. 
Various prototype MAP catheters, including modified 7 Fr mapping catheters, with four 
ball electrodes and two ring electrodes were used in this study (MAP4, Medtronic Inc.). 
Figure 2 shows the placement of MAP4 catheters on the endocardial surfaces of the right 
atrium (left) and the right ventricular apex (right). MAPs were recorded from the 
endocardial and epicardial surfaces of both the left and right sides of the heart.  Other 
catheters, not specifically designed to elicit MAP waveforms, were also studied to assess 
for potential design modifications to enable the recording of MAPs. 
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Figure 2. Endocardial catheters could be directly visualized while using the Visible Heart® apparatus for 
in vitro measurements. 
 
Results 
MAPs were recorded from both in-situ and in-vitro swine hearts using a variety of 
catheter designs. In both the in-situ (n = 23) and in vitro (n=51) studies, MAPs or MAP–
like waveforms were recorded from a variety of endocardial and epicardial locations from 
both the right and left sides of a given heart.  
As one specific example of the utility of employing Visible Heart® methodologies for 
catheter assessments, with the MAP4 catheter the tip consists of four electrodes 
approximately .9mm apart and with direct visualization we could study the relative effect 
of the catheter orientation.  More specifically, we were able to visualize when a given 
electrode was or was not in contact with the myocardial tissue and compare waveform 
results recorded from each of the ball electrodes. In Figure 3 the MAP4 was placed 
parallel to the right ventricular free wall; because two of the ball electrodes were not in 
contact with the tissue no MAP recordings were elicited for those two channels. On the 
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lower portion of the figure the catheter was placed in a pocket of tissue and MAPs were 
recorded on all four channels. This in turn, validates that a catheter designed with a multi-
array of MAP electrodes could be used as a means of potentially evaluating the relative 
device-tissue interface without direct visualization: e.g., which is the case of using 
fluoroscopy clinically.  
 
Figure 3. The Visible Heart® allows direct visualization of the device-tissue interface which can be used to 
evaluate prototype designs to record monophasic action potentials (MAPs). Shown here is a catheter with a 
poor device-tissue interface and MAPs only elicited on 2 of the 4 channels, in addition to a catheter with 
good device-tissue interface and MAPs on all 4 channels. 
 
In addition to the utilization of MAP4 catheters, other devices, not necessarily designed 
to record MAPs were evaluated using Visible Heart® methodologies. In the future, as 
various prototype mapping catheters and systems are developed we plan to utilize the 
benefits of studying them using the aforementioned in-situ/in-vitro comparisons. Within 
our laboratory, the hearts are fully functional in-vitro, which affords us a unique platform 
to readily assess the endocardial device/tissue interfaces.   
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Direct visualization of the device-tissue interface should also provide important insights 
that can be incorporated into device design, such as electrode shapes, spacing, sizes and 
orientations. Shown in Figure 4 is an example of a MAP recording elicited from a 
catheter that has not been optimized for recording MAPs (left). On the right is an 
example of how device optimization can improve these recordings. 
 
Figure 4. Seven channels of atrial signals recording using a catheter not optimized for monophasic action 
potential recordings (left) and a catheter that is (right, recordings from MAP4, Medtronic). 
 
Interpretation 
We describe here in-situ and in-vitro pre-clinical studies that were performed to gain 
novel insights as to cardiac catheter designs.  In part, the Visible Heart® methodologies 
were employed as a vital tool to allowing us to evaluate the designs of various mapping 
catheters, specifically with the ability to record Monophasic Action Potentials. Due to 
benefits of directly visualizing, the device-tissue interface during catheter placements, 
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coupled with improved ease to access a desired anatomical location, such pre-clinical 
methodologies should aid in expediting the designs of future catheters.  Furthermore, the 
obtained images should be of an educational benefit for future clinical use of these 
designed catheters by electrophysiologists.  
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Background 
Monophasic action potentials (MAPs) have long been used as a means to study the focal 
electrical activity of the myocardium [1, 2]. Upon the application of adequate contact 
force, the signals provide important insights into focal depolarization and repolarization, 
activation timing, and focal arrhythmic behaviors [3-6]. 
Within our laboratory we have developed an isolated physiologic, four-chamber working, 
large mammalian heart model (the Visible Heart® methodology) to study cardiac devices 
and their interactions with the myocardium [7]. Through the use of a modified Krebs-
Henseleit buffer, we can uniquely visualize the device-tissue interface: in this study, the 
placement of catheters. 
The purpose of this study was two-fold. First, we demonstrated the long term stability of 
MAP recordings in an in situ swine model. Second, we showed the relationship between 
MAPs recorded from in vitro and in situ preparations of each specimen.  
Methods 
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Swine (n=12) weighing between 70 and 80 kg were used in these studies. Animals were 
initially anesthetized with 500 mg of Telazol and 500 mg of Methohexital. The animals 
were then intubated and maintained in a plane of deep anesthesia (MAC > 1.2). A median 
sternotomy was performed, and a pericardial cradle was created to enable access to the 
epicardial surface of the heart [8]. Only specimens eliciting normal cardiac function (e.g., 
native sinus rhythm) were used. 
For the recording of MAPs, four 7Fr MAP4 catheters, (Medtronic, PLC, Dublin, IE) were 
used simultaneously. First one catheter was placed endocardially in the right ventricle 
(RV) through an introducer in the jugular vein. A second catheter was then placed 
endocardially in the right atrium (RA). Next two catheters were placed on the epicardial 
surface of the RV and the left atrium (LA). Catheter locations were verified by direct 
visualization for epicardial catheters and fluoroscopy (Ziehm Vision R) for endocardial 
locations, as can be seen in Figure 1. 
 
Figure 1. Location of MAPs catheter during in situ recordings. The image on the left shows the epicardial 
surface of the heart with 2 MAP4 catheters recording signals from the LA and the RV. The image on the 
right shows a fluoroscopic view of the MAP4 catheters (arrows) recording from the RA and RV 
endocardium. 
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MAP signals were recorded using a CardioLab Recording System (GE Healthcare, 
Waukesha, Wisconsin). Baseline signals were collected for 5 minutes with no 
disturbances of the catheters. This served as the baseline for each specimen to which all 
signals would be compared. Signals were then continuously collected and monitored for 
two hours, with only slight adjustments in catheter position to maintain constant tip 
pressure. 
Upon completion of in situ recordings, the heart was excised using previously described 
Visible Heart® methodologies. The heart was then reanimated, and MAPs were collected 
from the same 4 locations as seen in Figure 2.  
All results were analyzed in a custom MATLAB script. Significance was determined 
through the use of ANOVA and Tukey HSD with a p-value <0.05 considered significant.  
 
Figure 2. Location of MAPs catheter during in vitro recordings. The image on the left shows the epicardial 
surface of the re-animated heart with 2 MAP4 catheters recording signals from the LA and the RV. The 
images on the middle and right show the endocardial catheters in the RA and RV respectively. 
 
Results 
All MAP recordings were normalized to the 5 minute baseline recording collected in situ 
from the same specimen. There were two hypotheses to be tested in this experimental 
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procedure. First we examined the stability of MAP action potential duration at 90% 
repolarization (APD90) over long periods of in situ monitoring; in this case 2 hours. 
Second, we examined the relationship between APD90 from MAPs recorded in vitro, on 
the Visible Heart® prep, and their in situ baselines. Through the combination of these 
results we demonstrated that this system, the Visible Heart®, provides a unique platform 
for studying and testing next generation catheter designs. Statistical significance was 
determined using ANOVA with Tukey HSD, with significance being a p-value less than 
0.05. 
In situ comparisons 
The baseline recording from each catheter was compared to MAPs recorded at 30, 60, 90 
and 120 minute time points. For each location, there were no significant differences in 
APD90 between the baseline recordings and any measured time points. Figure 3 shows 
the normalized APD90s for each of the four catheters in situ over the 2 hour recording 
period.   
 
Figure 3. APD90 from in situ recordings normalized to their baseline recording for catheters on the RV 
epicardium and endocardium, RA endocardium and LA epicardium. There were no significant differences 
in normalized APD90 across any in situ time points. 
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In situ – in vitro comparisons 
The in situ baseline recording from each catheter was compared to in vitro signals 
recorded at 0, 30, 60, 90 and 120 minute time points. The 0 minute time point represents 
the minute immediately following re-animation, or the restoration of full cardiac 
function. APD90 for all signals was normalized to the baseline in situ recording. Only 
endocardial RA and epicardial LA catheters showed significant differences in APD90; 
and only for the 0 minute time point. Both the RV endocardial and epicardial catheters 
showed no significant differences when compared to their relative baselines. The 
normalized APD90s for each catheter can be seen in Figure 4.   
 
Figure 4. APD90 for in vitro recordings normalized to an in situ baseline recording for catheters on the RV 
epicardium and endocardium, RA endocardium and LA epicardium. The stars signify a significant 
difference from the in situ baseline for that location and time point. 
Interpretation 
The results mentioned in this paper have provided valuable insight into the recording of 
MAPs, both in situ and in vitro. 
Over a period of 2 hours MAPs were successfully recorded in situ with only minor 
adjustments in catheter position/pressure. There were no significant differences in 
APD90 for each location when compared to their normalized baseline values. Further 
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analysis of the relative amplitudes, depolarization rates and repolarization at other time 
points are being studied. 
Similarly, when looking at the in vitro recordings there were no significant differences 
between the endocardial and epicardial RV catheters when compared to their normalized 
in situ baselines. Future studies will examine these results at time points greater than 120 
minutes, to determine if there is a point at which the duration of the signals differ from in 
situ. 
The atrial MAP recordings showed a significant difference from their in situ baselines 
immediately after re- animation. It is hypothesized this response is due to ischemic injury 
that occurs during the isolation and re-perfusion processes. Interestingly, by 30 minutes 
into the in vitro prep there were no significant differences in APD90 for either the RA or 
LA MAP recordings. Further analyses will be conducted to determine how long it takes 
for these locations to reach non-significant values. 
From these results, we have gained two important insights into the recording of MAPs. 
First, the long-term monitoring of MAPs is possible with only slight adjustments in the 
catheter tip pressure and/or location. Second, the Visible Heart® methodologies are not 
only a viable tool for the imaging of the device tissue interface, but also for the 
recordings of monophasic action potentials and other electrical signals. With this new 
information, the development of catheters designed specifically to record MAPs can be 
continued using the Visible Heart® without compromised electrical activity, or 
diminished MAP signals. 
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